Tag Archives: Healthcare & Pharma

Brain-computer interface medical devices: China’s innovative registration policy direction

  • At the 2026 International Biomedical Industry Innovation Beijing Forum in Yizhuang, an official from the NMPA Medical Device Registration Management Department said brain-computer interface (BCI) has been incorporated into China’s 15th Five-Year Plan and written into the Government Work Report, and is positioned as a future industry.
    在2026国际生物医药产业创新北京论坛(北京亦庄)”神经调控与脑机接口技术产业发展论坛”上,国家药监局医疗器械注册管理司相关负责人表示,脑机接口已被纳入我国”十五五”规划、写入政府工作报告,明确作为未来产业予以布局。
  • The regulator signalled that supporting innovative registration and management policies will be introduced to systematically support the development and translation of BCI medical devices.
    药监部门表示将配套创新注册管理政策,系统支持脑机接口医疗器械的研发与落地转化。
  • As of end-July 2026, China had more than 347,000 valid medical-device registrations and filings; in 2025 the NMPA approved 14,187 medical-device registrations, up 8 per cent year on year.
    截至2026年7月底,全国有效医疗器械注册备案产品超过34.7万件;2025年国家药监局共批准医疗器械注册14187项,同比增长8%。
  • The “Spring Rain Action” clinical-translation programme has collected more than 400 Class III medical-device products and placed 22 quality projects into an expedited pre-review green channel.
    医疗器械临床创新成果转化”春雨行动”已征集400多个三类医疗器械产品,已有22个优质项目纳入审评前置绿色通道。
  • On standards, three industry standards for BCI have been issued, ten national standards and three industry standards are under development, and one international-standard proposal has been submitted, covering EEG acquisition, signal transmission, motor-intention decoding and device reliability.
    在标准方面,脑机接口领域已累计发布3项行业标准,立项10项国家标准、3项行业标准,并提交1项国际标准立项提案,覆盖脑电采集、信号传输、运动意图解码与设备可靠性等核心技术环节。
  • The regulator describes its approach as “front-loading regulation and standards first”, including pre-application technical guidance for both invasive and non-invasive products and unified naming and classification rules.
    监管方式被概括为”监管前置、标准先行”,包括对多款侵入式、非侵入式产品开展前置技术指导,并统一产品命名与分类界定规则。
  • For foreign companies the practical relevance is analytical rather than a formal commitment: the policy direction points to clearer registration pathways, but no specific BCI approval timelines, acceptance numbers or product names have been published.
    对境外企业而言,其实际意义属分析性判断而非官方承诺:政策方向指向更清晰的注册路径,但截至目前并未公布具体的脑机接口审批时限、受理编号或产品名称。

Brain-computer interface medical devices: China’s innovative registration policy direction | 脑机接口医疗器械:中国创新注册管理政策方向

Overview

In October 2026, the 2026 International Biomedical Industry Innovation Beijing Forum was held in Yizhuang, Beijing. At the forum’s “Neuromodulation and Brain-Computer Interface Technology Industry Development Forum”, an official from the Medical Device Registration Management Department of the National Medical Products Administration (NMPA) set out the regulator’s current reading of brain-computer interface (BCI) medical devices and the registration policy direction attached to them.

According to the remarks, BCI has been incorporated into China’s 15th Five-Year Plan and written into the Government Work Report, and is expressly positioned as a future industry. On that basis, the regulator said it would put in place supporting innovative registration and management policies to systematically support the research, development and translation of BCI medical devices.

The remarks are a policy-direction statement rather than a new rule. They describe how the existing medical-device registration system is being oriented towards BCI, and they rest on a set of published industry figures that show how the registration base and the innovation-support toolkit have grown.

Key developments

The official’s remarks combined a positioning statement with concrete numbers on China’s medical-device registration landscape.

  • Registration base. As of end-July 2026, China had more than 347,000 valid medical-device registrations and filings, spanning Class III registration certificates, Class II registration certificates and Class I filings.
  • Annual approvals. In 2025, the NMPA approved 14,187 medical-device registrations, an increase of 8 per cent year on year.
  • Clinical translation programme. The “Spring Rain Action” for the translation of clinical innovations in medical devices had collected more than 400 Class III medical-device products, covering high-end tracks such as BCI, interventional surgical robots, AI diagnostic software and high-end interventional implants and biomaterials. 22 quality projects had been placed into an expedited pre-review green channel.

Read together, these figures describe a large and still-growing registration pipeline, and a deliberate effort to move selected high-end products through review faster than the ordinary queue.

Standards first: the pre-review and standards toolkit

Alongside the registration figures, the remarks described the regulator’s operating approach as “front-loading regulation and standards first”.

On standards, the BCI field has seen:

  • three industry standards issued;
  • ten national standards and three industry standards initiated (立项); and
  • one international-standard proposal submitted.

The published standards cover core technical links including EEG acquisition, signal transmission, motor-intention decoding and device reliability.

On regulation, the approach includes:

  • advance planning of regulatory-science research;
  • pre-application technical guidance for a number of both invasive and non-invasive products; and
  • unified rules for product naming and classification.

The “standards first” logic matters for a technology like BCI, where the boundary between a medical device, a consumer wearable and a research instrument can be genuinely unclear. Naming and classification rules, and the existence of standards for core components, are the practical preconditions for a device to move into a defined registration pathway.

Next steps in regulation

The official set out the next steps in general terms: continuing to deepen reform of the medical-device review and approval system and to increase support for high-end innovative devices. Specific measures mentioned included:

  • optimising the review mechanism for “globally new” products;
  • providing front-loaded services such as clinical-trial pre-review and technical consultation; and
  • thereby accelerating the market launch of landmark products.

These are direction statements. They indicate where the regulator intends to concentrate facilitation effort, not the terms on which any individual product will be reviewed.

Practical implications for foreign companies

The following points are analytical observations, not official commitments. They describe what the policy direction may mean for foreign BCI and neurotechnology companies considering the China market.

  • The direction of travel is clearer, the details are not. A stated intent to build supporting innovative registration policies for BCI signals that the regulator is treating the field as a priority. It does not, on its own, change any filing requirement, and no BCI-specific approval timeline, acceptance number or product name has been published.
  • Classification and naming are the first practical questions. Because the regulator is unifying naming and classification rules for BCI, a company’s early task is to understand how its product would be classified and named under the Chinese system, since that determines the registration pathway.
  • Standards participation is a defined channel. With national and industry standards under development and an international-standard proposal submitted, there is an active standards-setting process. Foreign companies commonly monitor or participate in such processes through their China entities or industry associations, though the terms of participation follow the applicable standards rules.
  • Patent and intellectual-property positioning deserves early attention. BCI spans hardware, signal-processing algorithms and software. Companies usually review how their patent portfolio maps onto the Chinese classification and standards landscape before committing to a registration strategy. This is a commercial and legal planning point, not a statement of any regulatory preference.
  • Translation programmes are a signal, not a guarantee. The “Spring Rain Action” pipeline shows that a subset of high-end products is being routed into an expedited pre-review channel. Being in a high-priority field is relevant context, but selection for such programmes is a separate process.

Related considerations

For a foreign company, the sensible reading of these remarks is as a map of the regulator’s priorities rather than a set of entitlements. The registration figures show scale; the standards activity shows the field maturing towards defined technical requirements; and the “front-loading” language shows where facilitation effort is being directed. A company planning a China BCI strategy would typically combine this policy context with a product-specific review of classification, standards alignment, patent position and the appropriate registration pathway, and would confirm current requirements against the latest official publications before relying on any particular route.

Sources

  • 经济参考报 2026-10-08 报道(环球医药网转载)— 脑机接口纳入”十五五”规划与创新注册管理政策表态: https://www.qgyyzs.net/news/newshtml/hyxx/20261008090946.shtml
  • 中国政府网 — 未来产业与”十五五”规划政策背景: https://www.gov.cn/yaowen/liebiao/202610/content_7082824.htm
  • 中国网(受权发布)— 《关于发展新质生产力的意见》全文(含”前瞻布局未来产业”等产业定位表述): https://big5.china.com.cn/gate/big5/news.china.com.cn/2026-10/10/content_118727382.shtml

脑机接口医疗器械:中国创新注册管理政策方向

概述

2026年10月,2026国际生物医药产业创新北京论坛在北京亦庄举行。在该论坛的”神经调控与脑机接口技术产业发展论坛”上,国家药品监督管理局医疗器械注册管理司相关负责人就脑机接口医疗器械的监管现状与注册政策方向作了介绍。

据该负责人介绍,脑机接口已被纳入我国“十五五”规划、写入政府工作报告,明确作为未来产业予以布局。在此基础上,药监部门表示将配套创新注册管理政策,系统支持脑机接口医疗器械的研发与落地转化。

上述表态属政策方向性说明,而非新出台的规则。它描述的是现行医疗器械注册体系正如何向脑机接口领域倾斜,并以一组已公布的行业数据为依托,展示注册基数与创新支持工具的发展情况。

主要进展

该负责人的介绍将产业定位与具体数据结合在一起,勾勒出我国医疗器械注册的整体面貌。

  • 注册基数。 截至2026年7月底,全国有效医疗器械注册备案产品超过34.7万件,涵盖三类注册证、二类注册证及一类备案产品。
  • 年度批准量。 2025年,国家药监局共批准医疗器械注册14187项,同比增长8%。
  • 临床转化项目。 医疗器械临床创新成果转化“春雨行动”已征集400多个三类医疗器械产品,覆盖脑机接口、介入手术机器人、人工智能诊疗软件、高端植介入生物材料等高端赛道;已有22个优质项目纳入审评前置绿色通道。

综合来看,这组数据一方面说明注册管线规模庞大且仍在增长,另一方面也说明监管机构有意让部分高端产品以快于常规队列的方式通过审评。

标准先行:前置审评与标准工具箱

在注册数据之外,该负责人将监管机构的运行思路概括为“监管前置、标准先行”。

在标准方面,脑机接口领域已实现:

  • 累计发布3项行业标准;
  • 立项10项国家标准、3项行业标准;
  • 提交1项国际标准立项提案。

已发布的标准覆盖脑电采集、信号传输、运动意图解码、设备可靠性等核心技术环节。

在监管方面,相关做法包括:

  • 提前布局监管科学研究;
  • 对多款侵入式、非侵入式产品开展前置技术指导;
  • 统一产品命名与分类界定规则。

“标准先行”的逻辑对脑机接口这类技术尤为重要——医疗器械、消费级可穿戴设备与研究仪器之间的边界有时并不清晰。命名与分类界定规则,以及核心部件标准的建立,是产品得以进入明确注册路径的现实前提。

下一步监管方向

该负责人以总体表述方式提出了下一步方向:持续深化医疗器械审评审批制度改革,持续加大高端创新器械扶持力度。其中提到的具体举措包括:

  • 优化”全球新”产品审评机制;
  • 提供临床试验预审、技术咨询等前置服务;
  • 进而加速标杆产品上市。

这些属方向性表述,指示监管机构拟在何处集中便利化资源,并不等同于任何单一产品的审评条件。

对境外企业的实务意义

以下要点为分析性观察,并非官方承诺。它们描述的是该政策方向对考虑进入中国市场的境外脑机接口与神经技术企业可能意味着什么。

  • 方向更清晰,细节尚未明确。 表态提出将为脑机接口构建配套创新注册政策,说明监管机构将该领域视为优先方向。但这一表态本身并不改变任何申报要求,且截至目前并未公布脑机接口专属的审批时限、受理编号或产品名称。
  • 分类与命名是首要实务问题。 由于监管机构正在统一脑机接口的命名与分类界定规则,企业的早期工作之一是弄清其产品在中国体系下将被如何分类与命名,因为这决定了注册路径。
  • 参与标准化是一条既有通道。 随着国家标准与行业标准在研、国际标准提案已提交,标准化进程处于活跃状态。境外企业通常通过其在华主体或行业协会关注或参与此类进程,但参与条件须遵循适用的标准化管理规定。
  • 专利与知识产权布局宜及早关注。 脑机接口横跨硬件、信号处理算法与软件。企业通常会在确定注册策略前,先梳理其专利组合如何对应中国的分类与标准格局。这属商业与法律规划事项,并非监管倾向性表述。
  • 转化项目是信号,而非保证。 “春雨行动”管线显示,部分高端产品正被纳入审评前置快速通道。身处高优先级领域是相关背景,但能否入选此类项目是另一套独立程序。

相关考量

对境外企业而言,将上述表态理解为监管机构优先事项的路线图,比理解为一系列既得权益更为妥当。注册数据体现规模,标准化活动体现该领域正走向明确的技术要求,”前置”表述则体现便利化资源投入的方向。规划中国脑机接口战略的企业,通常会将这一政策背景与针对具体产品的分类、标准对齐、专利布局及相应注册路径评估结合起来,并在依赖任何具体路径前,依据最新官方发布确认现行要求。

来源

  • 经济参考报 2026-10-08 报道(环球医药网转载)— 脑机接口纳入”十五五”规划与创新注册管理政策表态: https://www.qgyyzs.net/news/newshtml/hyxx/20261008090946.shtml
  • 中国政府网 — 未来产业与”十五五”规划政策背景: https://www.gov.cn/yaowen/liebiao/202610/content_7082824.htm
  • 中国网(受权发布)— 《关于发展新质生产力的意见》全文(含”前瞻布局未来产业”等产业定位表述): https://big5.china.com.cn/gate/big5/news.china.com.cn/2026-10/10/content_118727382.shtml

Traditional Chinese Medicine Knowledge Protection: What the September 2026 Draft Regulation Means for Foreign Pharmaceutical and Healthcare Companies

  • On 18 September 2026, the State Council executive meeting reviewed and approved in principle the Draft Regulation on the Protection of Traditional Chinese Medicine Knowledge, describing traditional Chinese medicine theory, techniques and formulas as important resources for China’s own innovation and calling for comprehensive strengthening of protection and management.
    2026年9月18日,国务院常务会议审议通过《中医药传统知识保护条例(草案)》,会议指出中医药理论、技术和方药是我国自主创新的重要资源,要全面加强保护管理。
  • The regulation is to establish a protection system for traditional Chinese medicine knowledge: after registration and review-based recognition, a holder enjoys rights to indicate identity, to transmit and use, to informed consent, to benefit sharing, to integrity protection and to require disclosure of source, while medical institutions are encouraged to proactively investigate and develop proven formulas, secret formulas and techniques.
    条例将建立中医药传统知识保护制度:经登记并审核认定后,持有人享有表明身份、传承使用、知情同意、利益分享、完整保护、要求说明来源等权利,并鼓励医疗机构主动调查发现中医药验方、秘方和技法并进行开发研究。
  • The draft has not been published in full, so no article numbers, effective date, registration procedure or recognition thresholds are available; planning should rest on the official record as it appears.
    草案尚未公布全文,条款编号、生效日期、登记程序与认定门槛均无从确认;相关规划应以官方后续发布为准。
  • The IP Protection and Application 15th Five-Year Plan (State Council document No. 30 of 2026, issued on 27 July 2026) already lists “issuing the Regulation on the Protection of Traditional Chinese Medicine Knowledge” and strengthening access and benefit-sharing systems for traditional knowledge and folk literature and art.
    《知识产权保护和运用”十五五”规划》(国发〔2026〕30号,国务院2026年7月27日印发)已明确”出台中医药传统知识保护条例”,并加强传统知识、民间文艺等获取和惠益分享制度建设。
  • The same Plan directs improvement of intellectual property protection rules for algorithms and AI-generated output and exploration of data intellectual property protection rules, matters relevant to digital health and AI-assisted research.
    同一规划还提出完善算法、人工智能生成物等知识产权保护规则,探索构建数据知识产权保护规则,与数字健康及人工智能辅助研究密切相关。
  • The revised Trademark Law was adopted on 26 June 2026 and takes effect on 1 January 2027; it writes the principle of good faith into the law and targets bad-faith filings, trademark hoarding and agency conduct.
    新修订《商标法》于2026年6月26日通过、2027年1月1日施行,将诚实信用原则写入法律,并针对恶意抢注、商标囤积及代理行为作出规范。

Traditional Chinese Medicine Knowledge Protection: What the September 2026 Draft Regulation Means for Foreign Pharmaceutical and Healthcare Companies | 中医药传统知识保护:2026年9月国务院常务会议审议通过条例草案对外资医药与大健康企业的意义

Overview

On 18 September 2026, the State Council executive meeting reviewed and approved in principle the Draft Regulation on the Protection of Traditional Chinese Medicine Knowledge. In the official account, traditional Chinese medicine theory, techniques and formulas are described as important resources for China’s own innovation, and the requirement is to comprehensively strengthen their protection and management. The draft has not yet been published in full.

For foreign pharmaceutical, healthcare and wellness companies working in or with China, the development matters for a practical reason. It sits alongside a wider set of intellectual property measures that took effect or moved through the system in 2026, from the revised Trademark Law to the IP Protection and Application 15th Five-Year Plan. Together they shape how traditional knowledge, research collaboration and brand assets are documented and defended.

This article sets out the official wording, the protection system as described, the institutional arrangements in the 15th Five-Year Plan, and the practical points foreign companies may wish to consider. It deliberately does not speculate beyond the official record.

The September 2026 decision

The executive meeting approved the draft and set the direction of policy. Traditional Chinese medicine theory, techniques and formulas are treated as important resources for China’s own innovation, and the task set is to comprehensively strengthen protection and management.

The regulation is to establish a protection system for traditional Chinese medicine knowledge. Under that system, after registration and review-based recognition, a holder enjoys a set of rights: to indicate identity, to transmit and use the knowledge, to give informed consent, to share in benefits, to integrity protection, and to require disclosure of source.

The official account also encourages medical institutions to proactively investigate and discover traditional Chinese medicine proven formulas, secret formulas and techniques, and to carry out development and research on them.

Because the full text has not been published, no article numbers, effective date, registration procedure or definitional thresholds are available. Companies should treat any such details as pending until an official release appears, and should not rely on descriptions that circulate without an official source.

What the 15th Five-Year Plan already provides

The draft regulation is not an isolated initiative. The IP Protection and Application 15th Five-Year Plan (State Council document No. 30 of 2026, issued on 27 July 2026) had already placed it within a wider programme.

The Plan calls for accelerating improvement of the patent-related legal system, for comprehensively revising the Trademark Law and its implementing regulations, and for issuing the Regulation on the Protection of Traditional Chinese Medicine Knowledge. It also directs strengthening access and benefit-sharing systems for traditional knowledge, folk literature and art, and improving intellectual property protection rules for algorithms and AI-generated output as well as for platform-economy development. It further calls for exploring data intellectual property protection rules.

The Plan sets out milestones. By 2030, China’s comprehensive intellectual property strength and international competitiveness are to be further enhanced, with decisive progress in building an intellectual property power. Looking to 2035, comprehensive intellectual property competitiveness is to rank among the world’s leading.

For a company mapping its China research and brand strategy, the Plan is useful because it shows the direction of travel across several instruments at once rather than the detail of a single new rule.

Adjacent intellectual property developments in 2026

A nationwide briefing tour on new intellectual property rules began in Jinan on 20 September 2026, covering the Shandong and Anhui region. The briefings addressed three instruments.

The revised Trademark Law writes the principle of good faith into the law, targets bad-faith filings and the hoarding of trademarks, tightens supervision of trademark agencies and strengthens industry credit constraints. It was adopted on 26 June 2026 and takes effect on 1 January 2027.

The revised Regulation on the Protection of Layout Designs of Integrated Circuits brings layout designs performing functions such as integrated photonics and quantum into the statutory scope of protection and establishes an originality declaration system.

The revised Measures for the Prioritised Examination of Patents steer prioritised examination resources toward emerging industries and key core technology programmes, and establish a central-local coordination mechanism.

Read together with the traditional knowledge regulation, these measures point in a consistent direction: more explicit documentation of what is claimed, who holds it and where it came from.

Practical implications for foreign pharmaceutical and healthcare companies

Due diligence on traditional knowledge. Where a project touches formulas, techniques or sources of traditional knowledge, the rights described in the official account — identity, transmission and use, informed consent, benefit sharing, integrity protection and disclosure of source — suggest that provenance and consent questions may become part of the record. Companies may wish to document how a formula or technique was obtained and on what terms.

Collaboration agreements. Research with hospitals, institutes and practitioners should be documented, with clarity on background and foreground rights, on publication, and on how jointly created results are handled.

Patent and brand layout. The Plan’s direction on patents and the revised Trademark Law both reward early, well-documented filing strategies. A portfolio that depends on distinctive names and marks should be checked against the good-faith and bad-faith filing provisions as they take effect.

Digital and AI-related work. The Plan’s references to algorithms, AI-generated output and data intellectual property are relevant to digital health, AI-assisted screening and data-driven research, where ownership of outputs and datasets is often unsettled.

Watch the official record. Because the draft regulation is not yet published in full, the specific registration route, recognition criteria and benefit-sharing mechanics remain to be seen. Planning should be revisited when the text and any supporting measures are released.

Related considerations

Foreign-invested companies in the healthcare and wellness sectors already work within sector-specific rules on drugs, devices, healthcare services and advertising. The traditional knowledge regulation adds a knowledge-protection layer rather than replacing those rules. Keeping the two layers distinct — what may be made and sold, and what knowledge may be used and on what terms — helps avoid conflating a licensing question with a market-access question.

Sources

  • 国家知识产权局(《知识产权保护和运用”十五五”规划》专栏): https://www.cnipa.gov.cn/col/col3692/index.html
  • 酒泉市公安局(《知识产权保护和运用”十五五”规划》国发〔2026〕30号全文转载): https://gaj.jiuquan.gov.cn/gaj/c106483/202609/856895252998428d9990e67d9af39108.shtml
  • 国家知识产权局(官网,9月工作动态): https://www.cnipa.gov.cn/?filter=0
  • 大众网滨州(知识产权新规全国巡回宣贯,9月20日济南,9-23): https://www.toutiao.com/article/7688564714451780098/
  • 中国政府网: https://www.gov.cn/

中医药传统知识保护:2026年9月国务院常务会议审议通过条例草案对外资医药与大健康企业的意义

概述

2026年9月18日,国务院常务会议审议通过《中医药传统知识保护条例(草案)》。官方表述指出,中医药理论、技术和方药是我国自主创新的重要资源,要全面加强保护管理。该草案尚未公布全文。

对在华开展业务或与中国合作的外资医药、医疗健康与大健康企业而言,这一进展具有现实意义:它与2026年已经施行或正在推进的一揽子知识产权举措并列,从新修订《商标法》到《知识产权保护和运用”十五五”规划》,共同影响传统知识、研究协作与品牌资产的记录与维护方式。

本文梳理官方原文表述、条例拟确立的保护制度、规划中的制度安排,以及外资企业可能关注的实务要点,并刻意不作出超出官方记录范围的推断。

2026年9月的决定

国务院常务会议审议通过草案并确定了政策方向。中医药理论、技术和方药被视为我国自主创新的重要资源,任务要求是全面加强保护管理。

条例将建立中医药传统知识保护制度。在该制度下,经登记并审核认定后,持有人享有一组权利:表明身份、传承使用、知情同意、利益分享、完整保护、要求说明来源。

官方表述还鼓励医疗机构主动调查发现中医药验方、秘方和技法,并进行开发研究。

由于全文尚未公布,条款编号、生效日期、登记程序与认定门槛均无从确认。企业宜将此类细节视为待定,直至官方发布为止,不应依赖没有官方出处的描述。

“十五五”规划已作出的安排

该条例草案并非孤立举措。《知识产权保护和运用”十五五”规划》(国发〔2026〕30号,国务院2026年7月27日印发)已把它纳入更宏大的部署。

规划提出加快完善专利相关法律制度,推动商标法及其实施条例全面修改,并出台中医药传统知识保护条例。规划还提出加强传统知识、民间文艺等获取和惠益分享制度建设,完善算法、人工智能生成物以及与平台经济发展相关的知识产权保护规则,并探索构建数据知识产权保护规则。

规划设定了节点目标:到2030年,知识产权综合实力和国际竞争力进一步增强,知识产权强国建设取得决定性进展;展望2035年,知识产权综合竞争力跻身世界前列。

对正在规划中国研究与品牌战略的企业而言,该规划的价值在于,它一次性展示了多项制度工具的共同走向,而不只是一条新规的细节。

2026年相邻的知识产权进展

2026年9月20日,知识产权新规全国巡回宣贯在济南启动,覆盖山东、安徽片区。宣贯围绕三件法规展开。

新修订《商标法》将诚实信用原则写入法律,遏制恶意抢注、囤积商标,严格商标代理监管,强化行业信用约束。该法于2026年6月26日通过,2027年1月1日施行。

新修订《集成电路布图设计保护条例》将集成光子、量子等功能的集成电路布图设计纳入法定保护范围,并建立独创性声明制度。

修订后的《专利优先审查管理办法》使优先审查资源向新兴产业、关键核心技术攻关倾斜,并建立央地协同机制。

与中医药传统知识保护条例合并来看,这些举措指向一个一致的方向:对主张什么、由谁持有、来自何处作出更明确的记录。

对外资医药与大健康企业的实务影响

传统知识尽职调查。 当项目涉及方药、技法或传统知识来源时,官方表述中的权利——表明身份、传承使用、知情同意、利益分享、完整保护、要求说明来源——提示来源与同意问题可能进入记录范围。企业宜留存取得方药或技法的途径与条件的书面材料。

合作协议。 与医院、科研院所及从业者的研究合作应有书面安排,就背景权利与前景权利、发表,以及共同形成成果的处理作出清晰约定。

专利与品牌布局。 规划在专利方面的方向与新修订《商标法》都倾向于奖励尽早且记录充分的申请策略。依赖独特名称与标识的资产组合,宜在新法施行后比照诚实信用与恶意申请相关条款作一次核对。

数字与人工智能相关工作。 规划中关于算法、人工智能生成物与数据知识产权的表述,与数字健康、人工智能辅助筛查及数据驱动研究相关,而这些领域中成果与数据集的归属往往并不确定。

关注官方记录。 由于条例草案尚未公布全文,具体登记路径、认定标准与惠益分享机制仍有待观察。待文本及配套办法发布后,宜重新审视既有规划。

相关考虑

医药与大健康领域的外商投资企业,本就需遵循药品、器械、医疗服务与广告等分行业规则。中医药传统知识保护条例增加的是一个知识保护层面,而非取代上述规则。把两个层面区分开来——可以制造与销售什么,以及可以何种条件使用何种知识——有助于避免把许可问题与市场准入问题混为一谈。

来源

  • 国家知识产权局(《知识产权保护和运用”十五五”规划》专栏):https://www.cnipa.gov.cn/col/col3692/index.html
  • 酒泉市公安局(《知识产权保护和运用”十五五”规划》国发〔2026〕30号全文转载):https://gaj.jiuquan.gov.cn/gaj/c106483/202609/856895252998428d9990e67d9af39108.shtml
  • 国家知识产权局(官网,9月工作动态):https://www.cnipa.gov.cn/?filter=0
  • 大众网滨州(知识产权新规全国巡回宣贯,9月20日济南,9-23):https://www.toutiao.com/article/7688564714451780098/
  • 中国政府网:https://www.gov.cn/

Pharma and biotech opening moves from the foreign-investment action plan: segmented production, pilot expansion and the payment chain

  • The Action Plan for Stabilising and Optimising the Utilisation of Foreign Investment (商资发〔2026〕97号, issued 16 June 2026 by MOFCOM, NDRC and MOF) commits the government to “expedite the study and issuance of implementation rules for segmented pharmaceutical production”, easing cross-border segmented manufacturing of biologics and chemical drugs by foreign marketing-authorisation holders.
    商务部、国家发展改革委、财政部《利用外资固稳促优行动方案》(商资发〔2026〕97号,2026年6月16日印发)明确”抓紧研究出台药品分段生产实施细则”,便利境外药品上市许可持有人开展生物制品、化学药品跨境分段生产。
  • The same plan moves to widen pilot geography: authorities will “expedite research and approval to further expand the pilot regions for biotechnology and wholly foreign-owned hospitals” — the two most-watched restricted-service openings of the current cycle.
    同一方案还推动试点扩围:”抓紧研究报批进一步扩大生物技术、外商独资医院领域开放试点区域范围”——这是本轮最受关注的两项限制性服务业开放。
  • The statutory base is already in place: the revised Drug Administration Law Implementation Regulations (published January 2026) turned segmented production from pilot into institution, letting marketing-authorisation holders commission qualified producers to segment-manufacture innovative drugs and clinically urgent drugs when genuinely needed, under a unified quality-assurance system covering all sites.
    法定底座已经就位:修订后的《药品管理法实施条例》(2026年1月公布)把分段生产从试点推向制度——药品上市许可持有人确有需要的,可委托符合条件的企业分段生产创新药、临床急需药品等,并建立覆盖全部生产场地的统一质量保证体系。
  • Commercial proof-of-concept has landed: in May 2026 Johnson & Johnson’s niccalimab injection became the first imported biologic to run domestic segmented production of drug substance in China, with the substance made by WuXi Bio in Wuxi and fill-finish completed in Germany.
    商业验证已经落地:2026年5月,强生制药的尼卡利单抗注射液成为全国首个开展原液境内分段生产的进口生物制品——原液由无锡药明生物生产,制剂在德国完成。
  • Biotech opening pilots are producing registrable outcomes: under the 2024 pilot allowing FIEs to develop and apply human stem-cell and gene diagnosis and therapy technologies in designated free trade zones, at least six foreign companies — including Merck, JW Therapeutics-related entities, Frontera Therapeutics and StarCellBio — have completed registration changes or new filings.
    生物技术开放试点已产出可登记成果:在2024年允许外商投资企业于指定自贸区开展人体干细胞、基因诊断与治疗技术开发应用的试点下,至少6家外资企业(含默克、药明巨诺相关主体、芳拓生物、星奕昂等)已完成经营范围变更或新设登记。
  • Payment and channel measures complete the chain: the plan supports insurers in covering more innovative drugs and devices under commercial health insurance, and calls for an industry collaboration platform to smooth foreign-made pharmaceuticals into retail channels — the “last mile” that has capped foreign pharma revenue in China.
    支付与渠道措施补齐链条:方案支持保险公司将更多创新药械纳入商业保险保障范围,并搭建行业协作平台便利外资企业生产的药品进入零售渠道——这正是此前封顶外资药企中国收入的”最后一公里”。

Pharma and biotech opening moves from the foreign-investment action plan: segmented production, pilot expansion and the payment chain | 外资行动方案中的医药开放组合:分段生产、试点扩围与支付渠道

Overview

The Action Plan for Stabilising and Optimising the Utilisation of Foreign Investment (《利用外资固稳促优行动方案》, 商资发〔2026〕97号), issued on 16 June 2026 by the Ministry of Commerce, the National Development and Reform Commission and the Ministry of Finance with State Council consent, devotes one of its fifteen measures to pharmaceuticals. The measure assembles a “production — marketing-authorisation — payment — channel” package for foreign pharmaceutical and biotech companies: segmented production implementation rules, expanded pilot geography for biotechnology and wholly foreign-owned hospitals, commercial-insurance payment support, and retail-channel facilitation.

With September 2026 commentary from the Shanghai government’s weekly foreign-invested information service now tracking the package in detail, the measures are the clearest single statement of where foreign pharma market access in China is heading this cycle.

Segmented production: from pilot to statute to rules

Segmented production (分段生产) distributes a drug’s manufacturing process across sites or companies — globally common, but long restricted in China. The progression:

  • October 2024: the National Medical Products Administration issued the pilot work plan for segmented production of biologics, allowing certain innovative and clinically urgent biologics to run segmented production at the pilot stage.
  • January 2026: the State Council published the revised Drug Administration Law Implementation Regulations, moving segmented production into institution. Article 31 provides that where a marketing-authorisation holder genuinely needs it, the holder may commission qualified manufacturers to segment-manufacture (i) innovative drugs with special process, facility or equipment requirements, (ii) clinically urgent drugs and drugs needed for public-health response or reserves identified by the State Council departments, and (iii) other drugs specified by the drug regulator. The holder must build a unified quality-assurance system covering the whole production process and all sites; vaccines and blood products carry their own commissioning rules.
  • Next step: the action plan’s commitment to issue implementation rules for segmented pharmaceutical production — the operational layer for application conditions, quality-responsibility allocation and regulatory coordination.

The commercial template already exists: in May 2026, Johnson & Johnson’s niccalimab injection became the first imported biologic to run domestic segmented production of drug substance — substance produced by WuXi Biologics in Wuxi, fill-finish completed by Vetter Pharma in Germany. For multinationals, the case demonstrates the operating model the rules will generalise: foreign marketing-authorisation holders placing upstream segments with qualified Chinese CDMOs while keeping downstream finishing abroad, or the reverse.

Biotechnology and wholly foreign-owned hospitals: pilot expansion pending approval

Biotechnology (human stem cells, gene diagnosis and therapy) has been open to FIEs only inside designated pilot areas since September 2024, when Beijing, Shanghai and Guangdong free trade zones and Hainan were authorised. The registry shows results: at least six foreign companies — including Merck, entities associated with JW Therapeutics (药明巨诺), Frontera Therapeutics (芳拓生物) and StarCellBio (星奕昂) — have completed business-scope changes or new registrations inside the pilot areas.

The action plan instructs authorities to expedite research and approval for expanding the pilot regions for both biotechnology and wholly foreign-owned hospitals — the same two openings that Shanghai’s 15th Five-Year plan and other provincial documents name as landing priorities. Neither expansion has been formally approved yet; the plan converts the expansion from discussion item into an official workstream with a deadline pressure attached.

Payment and channels: the last-mile package

Two measures address the revenue side that has historically capped foreign pharma’s China performance:

  • Commercial insurance. The plan supports insurers in bringing more innovative drugs and devices into commercial health-insurance coverage — the payer channel that has grown fastest as national reimbursement negotiations compress prices.
  • Retail channels. An industry collaboration platform will be built to facilitate foreign-produced pharmaceuticals entering drug retail channels — addressing the distribution friction that has kept foreign-manufactured drugs out of pharmacy chains even after approval.

What this means for foreign pharma and healthcare groups

  • Map your product portfolio against segmented-production eligibility. The statutory categories are innovative drugs with special process/equipment requirements and clinically urgent or reserve drugs; groups with biologics or special-technology chemicals should identify candidates and pre-qualify Chinese CDMO partners under a unified quality system.
  • Watch the implementation rules, not just the plan. Application conditions, quality-responsibility division and regulatory coordination sit in the forthcoming rules; the drafting is the moment to submit practical comments.
  • Treat pilot expansion as a siting decision. If the biotech and wholly-owned-hospital pilots extend to new provinces, entity location inside a pilot area becomes a structuring variable; hold new China healthcare investments until the expanded map is published.
  • Build the commercial-insurance and retail strategy now. Payment support and retail-channel facilitation are revenue-side measures; groups that prepare health-insurance dossiers and pharmacy distribution agreements can move when the platforms land.
  • Benchmark against the niccalimab case. The first segmented-production precedent defines the documentation and quality-system expectations regulators will apply to the next applications.

Sources

  • 济源产城融合示范区管理委员会(转载)— 商务部 国家发展改革委 财政部关于印发《利用外资固稳促优行动方案》的通知(商资发〔2026〕97号,2026年6月16日,政府官网全文): https://zt.www.jiyuan.gov.cn/zsyz/wstz_zsyz/zcfb/t1008712.html
  • 上海市人民政府外事办公室 — 《上海资讯周报》涉外资讯一站式服务(2026年9月第1期,总第157期,2026年9月2日,医药开放组合与分段生产制度演进综述): https://wsb.sh.gov.cn/ztzl/shzxzb/20260902/d2eb54ce238e4d6d9f5bcac6e428f6e6.html
  • 蒙城县人民政府(转载)— 中华人民共和国药品管理法实施条例(2026年修订版分段生产条款第31—33条全文): https://www.mengcheng.gov.cn/XxgkContent/show/3008349.html

Related reading

  • see also: segmented pharma production pilot mechanics (segmented-pharma-production)
  • see also: wholly foreign-owned hospital pilot requirements (foreign-owned-hospital-pilot)

外资行动方案中的医药开放组合:分段生产、试点扩围与支付渠道

概述

《利用外资固稳促优行动方案》(商资发〔2026〕97号)由商务部、国家发展改革委、财政部经国务院同意于2026年6月16日印发,其十五条举措中专设一条指向医药。该条为外资医药与生物技术企业组装了一套”生产—上市许可—支付—渠道”组合:分段生产实施细则、生物技术与外商独资医院试点扩围、商业保险支付支持与零售渠道便利。

随着2026年9月上海市政府涉外资讯周报对该政策包作出详细追踪解读,这是本周期内中国外资药品准入走向最清晰的一份单项表述。

分段生产:从试点到法定再到细则

分段生产(分段生产)把药品生产过程分布在不同场地或企业之间——全球通行,但在中国长期受限。演进脉络:

  • 2024年10月: 国家药监局印发生物制品分段生产试点工作方案,允许部分创新生物制品和临床急需生物制品在试点阶段开展分段生产。
  • 2026年1月: 国务院公布修订后的《药品管理法实施条例》,把分段生产推向制度。第三十一条规定,药品上市许可持有人确有需要的,可以委托符合条件的药品生产企业分段生产:(一)生产工艺、设施设备有特殊要求的创新药;(二)临床急需药品、应对突发公共卫生事件急需或储备需要的药品;(三)国务院药品监督管理部门规定的其他药品。持有人须建立覆盖药品生产全过程和全部生产场地的统一质量保证体系;疫苗、血液制品另有委托生产规则。
  • 下一步: 行动方案承诺出台药品分段生产实施细则——即申请条件、质量责任划分与监管协调的操作层。

商业模板已经出现:2026年5月,强生制药的尼卡利单抗注射液成为全国首个开展原液境内分段生产的进口生物制品——原液由无锡药明生物生产,制剂由德国Vetter Pharma完成。对跨国药企而言,该案例演示了细则将要推广的运营模式:境外持有人把上游环节放在中国合格CDMO、下游制剂留在境外,或反向操作。

生物技术与外商独资医院:扩围报批中

自2024年9月北京、上海、广东自贸区和海南获准试点以来,生物技术(人体干细胞、基因诊断与治疗)仅对试点区域内FIE开放。登记情况已有产出:至少6家外资企业——包括默克、药明巨诺相关主体、芳拓生物(Frontera Therapeutics)、星奕昂等——已在试点区域内完成经营范围变更或新设登记。

行动方案要求抓紧研究报批进一步扩大生物技术、外商独资医院领域开放试点区域范围——上海”十五五”规划等省级文件点名的同样是这两项开放。扩围尚未正式获批;方案把扩围从讨论事项转为带时限压力的正式工作流程。

支付与渠道:最后一公里

两项措施指向历史上封顶外资药企中国收入的收入端:

  • 商业保险。 方案支持保险公司将更多创新药械纳入商业健康保险保障范围——在国家谈判压缩价格背景下增长最快的支付通道。
  • 零售渠道。 将搭建行业协作平台,便利外资企业生产的药品进入药品零售渠道——解决获批外资药品难以进入连锁药店的流通摩擦。

对外资医药与医疗集团的启示

  • 对照分段生产法定情形梳理产品组合。 法定类别是工艺设施有特殊要求的创新药与临床急需、储备药品;拥有生物制品或特殊工艺化学药的企业应识别候选产品,并按统一质量体系预审中国CDMO伙伴。
  • 盯细则而不止于方案。 申请条件、质量责任划分与监管协调都在即将出台的实施细则中;起草阶段是提交实务意见的窗口。
  • 把试点扩围当作选址变量。 若生物技术与独资医院试点扩展至新省份,主体落位在试点区域内就成为架构变量;新医疗投资可等扩围地图公布后再定。
  • 现在就建商保与零售策略。 支付支持与渠道便利是收入端措施;提前准备健康险材料与药店分销协议的集团,可在平台落地时立即行动。
  • 对标尼卡利单抗案例。 首个分段生产先例界定了监管对后续申请的单证与质量体系预期。

来源

  • 济源产城融合示范区管理委员会(转载)— 《利用外资固稳促优行动方案》通知全文(商资发〔2026〕97号): https://zt.www.jiyuan.gov.cn/zsyz/wstz_zsyz/zcfb/t1008712.html
  • 上海市人民政府外事办公室 — 《上海资讯周报》涉外资讯一站式服务(2026年9月第1期): https://wsb.sh.gov.cn/ztzl/shzxzb/20260902/d2eb54ce238e4d6d9f5bcac6e428f6e6.html
  • 蒙城县人民政府(转载)— 中华人民共和国药品管理法实施条例(分段生产条款全文): https://www.mengcheng.gov.cn/XxgkContent/show/3008349.html

相关阅读

  • 见:药品分段生产试点机制要点(segmented-pharma-production)
  • 见:外商独资医院试点要求(foreign-owned-hospital-pilot)

China professionalises the hospital channel for medical-nutrition foods: the FSMP Guiding Opinions

  • In late August 2026, the National Health Commission (NHC) and SAMR jointly issued the Guiding Opinions on Regulating the Use of Foods for Special Medical Purposes (FSMP) in Medical Institutions (document 国卫办食品发〔2026〕11号, dated 6 August 2026).
    2026年8月下旬,国家卫生健康委办公厅与市场监管总局办公厅联合印发《关于规范医疗机构特殊医学用途配方食品使用的指导意见》(国卫办食品发〔2026〕11号,成文日期2026年8月6日),面向各级各类医疗机构。
  • The Opinions define FSMP as formula foods registered by SAMR for sale on the domestic market, formulated for people with restricted eating, digestive-absorption disorders, metabolic disorders or specific disease states, and require use under the guidance of a physician or clinical nutritionist.
    指导意见界定:特医食品是指经国家市场监管部门注册可以在国内市场销售、为满足进食受限、消化吸收障碍、代谢紊乱或特定疾病状态人群对营养素或膳食的特殊需要专门加工配制的配方食品,须在医师或临床营养技师指导下使用。
  • Medical institutions must set up a dedicated FSMP management department or group, maintain a dynamic internal supply catalogue admitting only SAMR-registered products, and centralise selection, procurement, use and charging.
    医疗机构须确立特医食品使用管理部门或小组,建立并动态调整本机构《特殊医学用途配方食品供应目录》,只允许经国家注册的特医食品进入目录,并对遴选、采购、使用、收费进行集中统一管理。
  • Within hospitals, FSMP must be sold in a clearly marked dedicated zone or counter (“特殊医学用途配方食品销售专区/专柜”), sale and usage information must be recorded and retained to medical-record standards, and FSMP must not be prescribed as medicine — it is not a drug, so no prescriptions, and billing must be separated from pharmaceuticals.
    院内管理上,特医食品须设专区专柜销售并显著提示;销售信息(含患者信息、品名、规格、价格)记录保存时限参照病历;特医食品不属于药品、不得开具处方,发放与收费须与药品区分。
  • For imported and domestic FSMP producers and their distributors, the guidance professionalises the hospital channel: registration status will be verified at the hospital gate, procurement and recall co-operation with institutions is formalised, and marketing into hospitals must shift from prescription-style promotion to compliance-based clinical-nutrition education.
    对国内外特医食品企业与经销商而言,新规使医院渠道走向专业化:注册资质在医院门口被核验,采购与召回配合被制度化,面向医院的推广须从”类处方”促销转向合规的临床营养教育。

China professionalises the hospital channel for medical-nutrition foods: the FSMP Guiding Opinions | 特医食品医院渠道走向规范化:两部门出台医疗机构使用指导意见

Overview

The National Health Commission (NHC) and the State Administration for Market Regulation (SAMR) jointly issued the Guiding Opinions on Regulating the Use of Foods for Special Medical Purposes (FSMP) in Medical Institutions (《关于规范医疗机构特殊医学用途配方食品使用的指导意见》) in late August 2026, with the document dated 6 August 2026 and publicised around 26–30 August. The Opinions, issued under the Food Safety Law and the Regulations on the Administration of Medical Institutions, apply to the selection, sale and use of FSMP within all types and levels of medical institutions in China. They mark the first time the national authorities have set out a complete operational framework for how hospitals should manage, stock, sell and use FSMP — a category that sits at the intersection of food, nutrition and clinical care.

What FSMP are — and why they need special rules

FSMP are formula foods that have been registered by SAMR for sale on the domestic market, specially processed and formulated to meet the nutritional or dietary needs of people with restricted eating, digestive or absorption disorders, metabolic disorders, or specific disease states. They provide important nutritional support for treatment, rehabilitation and maintenance of bodily function in these populations. Because they look like medical products but are legally food, they have historically sat in an ambiguous zone: food law governs their registration, yet their practical use is clinical, and hospitals have lacked uniform rules on procurement, pricing, storage and use.

The Opinions restate the fundamental boundary: FSMP must be used under the guidance of a physician or clinical nutritionist, and they are not drugs. The document applies to medical institutions holding a Medical Institution Practicing Licence or clinic-filing certificate.

Three layers of institutional rules

1. Governance structure. Each medical institution must establish a dedicated FSMP management department or group, build and dynamically adjust its own internal FSMP supply catalogue, verify product qualifications, and admit only FSMP registered by SAMR. The institution must set up rules for selection, review, procurement, use, periodic evaluation and exit, managing FSMP centrally and standardising the processes for receiving, using and charging.

2. In-hospital management systems. Institutions must take effective control measures across procurement, storage, sale and use; establish and refine systems for incoming-goods inspection and record-keeping (进货查验记录制度), warehouse management, in-and-out management, and handling of non-conforming FSMP; and designate personnel responsible for food-safety management. Practitioners involved in FSMP use — physicians or clinical nutritionists — should have clinical-nutrition education or training, plus FSMP-use knowledge and standardised-management training.

3. Clinical-use discipline. Practitioners should follow a standardised nutrition-diagnosis-and-treatment pathway, giving priority to dietary guidance and only proposing FSMP where dietary intervention cannot meet clinical needs and there are clinical indications. When recommending FSMP, they should explain the product’s details and its non-drug nature, whether alternative food or medicine exists, and obtain patient or family consent where used. FSMP use during a hospital stay should be recorded in the medical record, and the institution’s FSMP management department or group should evaluate the standardisation and reasonableness of use.

Selling and charging rules that matter commercially

Four operational rules are particularly important for producers and distributors:

  • Dedicated zone or counter. Institutions that sell FSMP must set up a separate sales area with a prominent sign reading “特殊医学用途配方食品销售专区(或专柜)”.
  • Record retention. Sales information — including patient information, FSMP name, specification and price — must be recorded and kept for a retention period consistent with medical records. This is a significant compliance consideration under the Personal Information Protection Law for patient-related data.
  • No prescriptions; separate billing. FSMP are not drugs, so they cannot be prescribed; their distribution and charging must be separated from pharmaceuticals. Institutions are encouraged to adopt information-system coding management that brings FSMP sales and use into hospital information systems.
  • No coercion. It is prohibited to sell or use, in the name of FSMP, any food that is not registered or that implies it can meet the special nutritional or dietary needs of the target populations. It is also prohibited to force or induce patients to buy FSMP in the institution or at designated outlets.

Recall co-operation

Institutions must co-operate with FSMP producers on recalls: once aware that a producer is recalling unsafe FSMP, the institution must immediately stop selling and seal the product and post a recall notice in a prominent position. Producers should therefore ensure their recall procedures reach hospital customers promptly and are documented.

What this means for producers and distributors

  • Registration is the admission ticket to the hospital channel. Hospitals may only list SAMR-registered FSMP in their supply catalogues. For importers, this reinforces the existing requirement to hold a Chinese registration for each product sold in China; products without registration cannot legally enter the hospital channel regardless of clinical demand.
  • The path to hospital formulary entry is now formal. Producers should expect hospital procurement to be run through the dedicated management group, with qualification review, and periodic re-evaluation. Building clinical-nutrition evidence and co-operation with nutrition departments — rather than prescription-oriented promotion — becomes the compliant route to market access.
  • Compliance burden moves down the chain. Distributors serving hospitals must ensure that labelling, storage and delivery meet the dedicated-zone and traceability expectations, and that patient-related sales data handling complies with privacy rules.
  • Regional variation is expected. The Opinions acknowledge that regions differ in economic development, medical-resource allocation and clinical-nutrition development, and encourage local implementation adapted to local conditions. Producers should track provincial implementation measures.
  • Opportunity in the nutritional-support gap. With an ageing population and growing awareness of clinical nutrition, FSMP remain a growth category; clearer rules that professionalise the hospital channel can favour compliant, well-evidenced brands — domestic and foreign alike.

Practical steps

  • Verify that every FSMP product marketed into China holds a valid SAMR registration matching the exact formula and label in use.
  • Prepare hospital-facing materials that support nutrition-department education and formulary review (clinical evidence summaries, usage guidance compliant with non-drug positioning).
  • Ensure recall plans include hospital customers and rapid notification mechanisms.
  • Review distributor agreements for compliance with dedicated-zone sale, record-retention and no-coercion rules.
  • Monitor provincial implementation guidance and adjust sales models per region.

Sources

  • 市场监管总局 — 国家卫生健康委办公厅 市场监管总局办公厅关于规范医疗机构特殊医学用途配方食品使用的指导意见(全文): https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/tssps/art/2026/art_81290de7385d4573939b6790103a5fb1.html
  • 市场监管总局(新闻)— 两部门联合出台指导意见 规范医疗机构使用特殊医学用途配方食品: https://www.samr.gov.cn:8007/xw/zj/art/2026/art_b34e6b283ecf4530a93aef63c6194e9f.html
  • 毕节市人民政府(政策解读转载)— 划红线、建目录、禁开处方!国家出台新规规范特医食品使用: https://www.bijie.gov.cn/bm/bjswsjkj/zwgk/zcwjjjd/202608/t20260831_90801118.html
  • 人民网湖北频道 — 国家卫生健康委等规范医疗机构特医食品使用管理: https://hb.people.com.cn/n2/2026/0831/c192237-41681914.html

Related reading

  • see also: China’s FSMP registration regime — the 2024 Administrative Measures baseline (fsmp-registration-measures)
  • see also: medical-device and pharma market entry routes into Chinese hospitals (healthcare-market-access)

特医食品医院渠道走向规范化:两部门出台医疗机构使用指导意见

概述

2026年8月下旬,国家卫生健康委办公厅与市场监管总局办公厅联合印发《关于规范医疗机构特殊医学用途配方食品使用的指导意见》(成文日期2026年8月6日,8月26日前后对外发布)。指导意见依据《食品安全法》《医疗机构管理条例》等法律法规制定,适用于各级各类医疗机构内特医食品的遴选、销售与使用,是国家层面首次为医院如何管理、采购、销售和使用特医食品建立完整操作框架。特医食品正处于食品、营养与临床照护的交叉地带,此前的管理长期存在模糊区。

什么是特医食品——以及为何需要专门规则

特医食品是指经国家市场监管部门注册可以在国内市场销售,为满足进食受限、消化吸收障碍、代谢紊乱或特定疾病状态人群对营养素或膳食的特殊需要,专门加工配制而成的配方食品。对这些人群的治疗、康复及机体功能维持起着重要营养支持作用。它看起来像医疗产品、法律上却是食品:注册环节适用食品法,实际使用却是临床行为,医院在采购、定价、储存与使用上长期缺乏统一规则。

指导意见重申根本边界:特医食品须在医师或临床营养技师指导下使用,且不属于药品。文件适用于持有《医疗机构执业许可证》或诊所备案凭证、依法从事疾病诊断和治疗活动的诊疗机构。

三层制度要求

一、治理架构。 医疗机构须确立特医食品使用管理部门或小组,建立并动态调整本机构《特殊医学用途配方食品供应目录》,审核产品资质,只允许经国家市场监管部门注册的特医食品进入目录。医院要建立遴选、审核、采购、使用、定期评估和退出制度,对特医食品集中统一管理,规范领取、使用与收费流程。

二、院内管理制度。 医院须在采购、贮存、销售及使用等环节采取有效控制措施,建立健全进货查验记录制度、仓储场所管理制度、出入库管理制度及不合格特医食品处置制度,明确负责食品安全管理的人员。从事特医食品使用工作的医师或临床营养技师等,应经过临床营养专业教育或培训,以及特医食品使用知识和规范化管理培训。

三、临床使用规范。 医师或临床营养技师应严格遵照规范化营养诊疗流程,优先提出膳食指导建议;膳食干预无法满足临床需求时,方可根据临床应用指征提出必要的特医食品使用建议。提出建议时应说明食品详情和非药品属性、是否有可替代的食品或药品,使用应征得患者或家属同意。患者住院期间使用特医食品的情况应记入病历,医院特医食品使用管理部门或小组应组织评估使用规范性与合理性。

对商业运营至关重要的销售与收费规则

以下四项操作性规则对生产企业和经销商尤其关键:

  • 专区专柜。 医疗机构经营特医食品,应设专门的销售区域,显著位置设提示牌,注明”特殊医学用途配方食品销售专区(或专柜)”字样。
  • 信息留存。 对销售信息(含患者信息、特医食品名称、规格、价格)进行记录和保存,保存时限参照病历。涉及患者信息的数据处理须同时符合《个人信息保护法》等要求。
  • 不得开处方、收费分离。 特医食品不属于药品、不得开具处方,其发放、收费等应当与药品区分;鼓励有条件的机构做好信息业务编码管理,将特医食品销售和使用项目纳入院内信息系统。
  • 禁止强制销售。 严禁以特医食品名义销售或使用未经国家注册批准、明示或暗示可用于满足目标人群特殊营养或膳食需要的食品;严禁强制或诱导患者在本机构或到指定地点购买。

召回配合

医疗机构应配合特医食品生产企业开展召回:一旦知悉企业召回不安全特医食品,应立即停止销售并封存、在醒目位置张贴召回公告。生产企业应确保召回程序能及时触达医院客户并留存记录。

对企业与经销商的意义

  • 注册资质是进入医院渠道的门票。 医院目录只接纳经国家注册的特医食品。进口商须为在华销售的每个产品持有有效中国注册证;无注册证的产品无论临床需求多大都无法合法进入医院渠道。
  • 进入院内目录的路径正式化。 生产企业应预期采购由专门管理小组按资质审核与定期再评估流程运作。建立临床营养证据、与营养科开展合规合作,而非”类处方”式促销,成为合规的市场准入路径。
  • 合规压力沿渠道下移。 服务医院的经销商须确保标签、储存与配送满足专区与可追溯预期,涉患者销售数据的处理符合隐私规则。
  • 地区差异可期。 指导意见承认各地在经济发展水平、医疗资源配置与临床营养学科建设上存在差异,鼓励各地结合本地实际实施。企业应跟踪省级落实细则。
  • 营养支持缺口中的机遇。 在人口老龄化与临床营养意识提升背景下,特医食品仍是增长品类;医院渠道专业化的清晰规则,将有利于合规、有证据的国内外品牌。

实务建议

  • 核验在华销售的每个特医食品产品均持有与在用配方、标签一致的有效的国家注册证。
  • 准备面向医院的合规材料,支持营养科教育与目录评审(临床证据摘要、符合非药品定位的使用指引)。
  • 确保召回计划覆盖医院客户并具备快速通知机制。
  • 审查经销商协议,确保其遵守专区销售、记录留存与禁止强制销售规则。
  • 跟踪各省级实施指引,分区域调整销售模式。

来源

  • 市场监管总局 — 国家卫生健康委办公厅 市场监管总局办公厅关于规范医疗机构特殊医学用途配方食品使用的指导意见(全文): https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/tssps/art/2026/art_81290de7385d4573939b6790103a5fb1.html
  • 市场监管总局(新闻)— 两部门联合出台指导意见 规范医疗机构使用特殊医学用途配方食品: https://www.samr.gov.cn:8007/xw/zj/art/2026/art_b34e6b283ecf4530a93aef63c6194e9f.html
  • 毕节市人民政府(政策解读转载)— 划红线、建目录、禁开处方!国家出台新规规范特医食品使用: https://www.bijie.gov.cn/bm/bjswsjkj/zwgk/zcwjjjd/202608/t20260831_90801118.html
  • 人民网湖北频道 — 国家卫生健康委等规范医疗机构特医食品使用管理: https://hb.people.com.cn/n2/2026/0831/c192237-41681914.html

相关阅读

  • 见:中国特医食品注册管理——《注册管理办法》(2024年施行)基线(fsmp-registration-measures)
  • 见:药品与医疗器械进入中国医院市场的路径(healthcare-market-access)

China’s drug traceability rules harden: full coding, full scanning from NMPA Announcement No. 85 of 2026

  • On 1 September 2026, the National Medical Products Administration (NMPA) published Announcement No. 85 of 2026 on Further Strengthening the Administration of Drug Information Traceability (dated 31 August 2026), demanding full-variety coding (“应赋尽赋”) and full-chain scanning (“见码必扫”).
    2026年9月1日,国家药监局发布《关于进一步加强药品信息化追溯管理工作的公告》(2026年第85号,落款2026年8月31日),提出”全品种赋码、应赋尽赋,全链条扫码、见码必扫”的总要求。
  • The announcement hardens legal duties across the whole chain — marketing-authorisation holders (MAHs), domestic agents of overseas MAHs, manufacturers, distributors, medical institutions and traceability-system operators — and, with limited exceptions (active pharmaceutical ingredients, medical oxygen, hospital preparations), all finished dosage forms in production must be coded; TCM decoction pieces follow separate rules.
    公告压实持有人、境外持有人指定境内责任人、生产企业、经营企业、使用单位及追溯系统运营单位等各方责任;除原料药、医用氧、医疗机构制剂等少数品类外,全部在产制剂品种均须赋码(中药饮片追溯要求另行制定)。
  • Code registration is tightened: MAHs and domestic agents must file drug identifier codes on the national co-ordination platform through the NMPA government-service portal and link identifier code, commodity bar code, national drug code and medical-insurance code; issuing bodies and system operators must also file to guarantee uniqueness.
    追溯码备案趋严:持有人、境内责任人须通过国家药监局政务服务门户登录国家药品追溯协同服务平台,及时准确完整备案药品标识码,完成标识码、商品条码、本位码、医保编码等多码关联;发码机构与系统运营单位须向平台备案以确保唯一性。
  • Distributors and end-users face hard scanning rules: wholesalers must treat code verification as a mandatory part of inbound acceptance and upload information on outbound review; pharmacies and medical institutions must verify codes on inbound acceptance, upload sales records, and refuse goods whose traceability shows they were already sold at another retail outlet; abnormal alerts require stopping sales pending quality-manager review.
    经营使用环节扫码成为硬性流程:批发企业须把扫码核对作为入库验收的必须内容并在出库复核时上传信息;零售药店与医疗机构入库验收须核对追溯码、销售时上传销售信息;发现追溯信息显示药品已在其他零售或使用单位售出的应拒收;出现异常预警应立即停止入库和销售,由质量负责人审核签字后处理。
  • For pharmaceutical companies importing into China and their local partners, the message is that traceability has moved from infrastructure-building to routine enforcement: performance will be woven into daily inspections by provincial drug administrations, with tampering or fabrication of traceability data punished under the Drug Administration Law and GSP-related rules.
    对进口药品企业与本地合作伙伴而言,信号明确:药品追溯已从”建基础设施”进入”常态化监管执法”阶段——省级药监部门将把追溯落实情况纳入日常检查,篡改、伪造追溯数据或不落实追溯义务者将依《药品管理法》《药品经营和使用质量监督管理办法》等严肃处理。

China’s drug traceability rules harden: full coding, full scanning from NMPA Announcement No. 85 of 2026 | 药品追溯进入”全品种全链条”强监管:国家药监局2026年第85号公告解读

Overview

On 1 September 2026, the National Medical Products Administration (NMPA) published Announcement No. 85 of 2026 on Further Strengthening the Administration of Drug Information Traceability (《国家药监局关于进一步加强药品信息化追溯管理工作的公告(2026年第85号)》), dated 31 August 2026. Building on the Drug Administration Law and its implementing regulations, the announcement consolidates years of pilot infrastructure into a compulsory, enforceable regime: every product coded, every code scanned, and every link answerable. NMPA officials described the drug traceability code as each pack’s “electronic identity card”, capable of recording where a product has been approved and how it moved through production and distribution.

The core principle: 应赋尽赋, 见码必扫

The announcement states the overall requirement as “full-variety coding — everything that should be coded must be coded; full-chain scanning — every code that appears must be scanned”. The coverage is nearly universal: with the exceptions of active pharmaceutical ingredients, medical oxygen and hospital preparations, all finished dosage forms in production fall within the traceability scope. Traditional Chinese medicine decoction pieces are governed by separate rules to be issued. This means imported finished drugs distributed in China are squarely within the regime, and their MAHs and domestic agents carry the first-layer obligations.

Duties by link in the chain

MAHs and domestic agents of overseas MAHs (持有人、境内责任人). They must:

  • file drug identifier codes through the NMPA government-service portal on the national drug traceability co-ordination platform, accurately and completely, linking the identifier code, commodity bar code, national drug code (本位码) and medical-insurance code;
  • follow the “one object one code, code and object tracked together” (一物一码、物码同追) principle, completing traceability-code activation before market launch, linking codes across all levels of sales packaging, and uploading traceability information accurately and promptly;
  • save in-warehouse records in the traceability system at finished-goods receipt, provide downstream traceability information at outbound sale, and promptly handle abnormal-code feedback from downstream parties so that information remains truthful and credible.

Manufacturers (生产企业). Alongside MAHs, they are responsible for coding activation and packaging-linkage before products are placed on sale, and for accurate, timely uploads.

Wholesale distributors (批发企业). Inbound acceptance must include obtaining traceability information from the upstream party and verifying the traceability code as a mandatory part of acceptance; they must feed receipt information back upstream and, at outbound-sale review, provide traceability information to downstream enterprises or medical institutions through the system.

Retail pharmacies and medical institutions (零售药店、医疗机构). On inbound acceptance they must verify codes against the upstream party and feed receipt information back; when selling, they must keep detailed sales records and upload sales information through the traceability system in a timely manner. Sales receipts must display the traceability code or offer another convenient query channel for consumers. Where the system raises an abnormal alert, the pharmacy or institution must immediately stop inbound acceptance and sales, verify and handle the alert, with the measures signed off by the quality manager and records kept per GSP requirements. Where inbound acceptance reveals traceability information showing the drug was already sold at a retail pharmacy or medical institution, the goods must be refused.

Traceability-system operators (追溯系统运营单位). They must maintain public-interest orientation, guarantee data security, provide recall support for MAHs and domestic agents, offer real-time early warning of abnormal traceability signals at inbound acceptance for wholesale, retail and user units, protect personal privacy and trade secrets in traceability data, and not disclose or illegally provide data to others. They must file with the national platform to ensure code uniqueness.

Supervision and enforcement

The announcement asks provincial drug administrations to make traceability performance part of daily inspection of enterprises and units in their regions, pushing full-variety coding activation and full-chain scanning and uploading (“应赋尽赋、应扫尽扫”). Entities that fail to comply with the regulations or with traceability requirements are to be handled seriously under the Drug Administration Law, the Measures for the Supervision and Administration of Drug Operation and Use, and the Good Supply Practice (GSP) rules. NMPA also stresses “三医协同” — co-ordination among the drug, medical-insurance and health authorities — and the use of traceability data for smart supervision, risk discovery and rapid handling. The data-security angle is explicit: system operators must build data-security management institutions under the Data Security Law and keep private and commercial data confidential.

Why this matters to foreign pharmaceutical companies

  • Traceability compliance is now an enforcement matter, not a project. Foreign MAHs importing finished drugs must ensure their domestic agent (境内责任人) operates the full coding-and-uploading cycle on the national platform. The agent is a regulated extension of the MAH; a weak agent means personal exposure for the MAH’s China compliance posture.
  • Multi-code linkage affects packaging and IT work. Linking the identifier code, commodity bar code, national drug code and medical-insurance code means packaging data and enterprise resource systems must be reconciled with Chinese regulatory identifiers before first import. Imported products already carrying GS1 codes still need the Chinese identifier-code linkage.
  • Channel discipline improves for compliant players. The rule that goods already sold elsewhere must be refused, and that abnormal alerts stop sales, directly attacks “reflux drugs” (回流药) and code-swapping fraud — problems that undercut legitimate pricing. Compliant importers benefit as grey channels close.
  • GSP-grade documentation is required across the distributor network. Distributors’ inbound/outbound scanning and the quality-manager sign-off on abnormal alerts become audit evidence; foreign firms should verify their Chinese distributors’ systems actually generate this documentation.
  • Co-ordination with medical-insurance settlement. NMPA links traceability to medical-insurance code-based settlement; announcements and practice increasingly tie code verification to reimbursement and anti-fraud work, so products without sound traceability data may face friction in hospital and insurance-channel reimbursement.

Practical steps

  • Confirm that the domestic agent of each imported MAH has an up-to-date registration on the national traceability co-ordination platform with correct multi-code linkage for every marketed SKU.
  • Audit packaging and labelling projects to ensure traceability codes, bar codes and hierarchy linkage are complete before first shipment into China.
  • Review distributor contracts to require GSP-compliant inbound/outbound scanning, abnormal-alert handling and quality-manager sign-off records.
  • Align internal ERP/quality systems with the platform’s data-upload requirements, including timely handling of downstream abnormal-code feedback.
  • Monitor provincial enforcement and any TCM-decoction-piece traceability rules still to be issued, and track the interaction between traceability and medical-insurance settlement in tender and hospital channels.

Sources

  • 国家药监局 — 国家药监局关于进一步加强药品信息化追溯管理工作的公告(2026年第85号): https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260901134430105.html
  • 医药网 — 药品追溯新规出台 压实全产业链主体监管责任: https://news.pharmnet.com.cn/news/2026/09/02/625299.html
  • 央视新闻(辽宁药监转载)— 视频丨国家药监局:药品追溯须覆盖全品种全链条: https://www.toutiao.com/article/7681111672232100387

Related reading

  • see also: China’s drug import licensing and GSP obligations for foreign MAHs (drug-import-licensing-gsp)
  • see also: medical-device UDI roll-out and the parallel “drug-device same-traceability” agenda (medical-device-udi)

药品追溯进入”全品种全链条”强监管:国家药监局2026年第85号公告解读

概述

2026年9月1日,国家药监局发布《关于进一步加强药品信息化追溯管理工作的公告》(2026年第85号,落款2026年8月31日)。公告依据《药品管理法》及其实施条例制定,把多年试点形成的基础设施升级为强制性、可执行的全链条制度:每个产品赋码、每个码必扫、每个环节可追责。药监局官员将药品追溯码形容为每一盒药的”电子身份证”,扫码即可记录和获取药品获批及生产流通环节的详细信息。

总原则:应赋尽赋、见码必扫

公告确立的总要求是”全品种赋码、应赋尽赋;全链条扫码、见码必扫”。覆盖面近乎全面:除原料药、医用氧、医疗机构制剂等少数品类外,全部在产制剂品种纳入追溯范围;中药饮片追溯要求另行制定。这意味着在华流通的进口制剂同样完全落入该制度,其持有人与境内责任人承担第一层义务。

各环节义务

持有人、境外持有人境内责任人。 须:通过国家药监局政务服务门户登录国家药品追溯协同服务平台,及时、准确、完整备案药品标识码,完成标识码、商品条码、本位码、医保编码等多码关联;按照”一物一码、物码同追”原则,在上市销售前完成追溯码赋码激活、各级销售包装单元追溯码关联并及时准确上传追溯信息;成品入库时在追溯系统保存入库信息,销售出库时向下游企业或使用单位提供追溯信息;及时处理下游反馈的追溯码异常信息,保障信息真实可信。

生产企业。 与持有人共同落实赋码激活与包装层级关联,及时准确上传信息。

批发企业。 入库验收时必须通过追溯系统向上游索取追溯信息、进行追溯码核对,将扫码核对作为入库验收的必须内容并反馈收货信息;出库复核时向下游企业或医疗机构提供追溯信息。

零售药店与医疗机构。 入库验收时与上游核对追溯码并反馈收货信息;销售时保存销售记录明细并及时上传销售信息;销售小票应显示追溯码或提供便捷查询渠道。追溯系统出现异常预警的,应立即停止入库和销售,核实处理并由质量负责人审核签字后实施,按GSP要求保存记录。入库验收发现追溯信息显示该药品已在其他零售或使用单位售出的,应当拒收。

追溯系统运营单位。 坚持公益性导向,保障数据安全;为持有人、境内责任人提供召回支持;为批发、零售、使用单位提供入库环节异常信号实时预警;对追溯信息中可能含有的个人隐私、商业秘密依法保密,不得泄露或非法提供;向国家平台备案确保追溯码唯一性。

监管与执法

公告要求各省级药监部门把追溯落实情况纳入对企业和单位的日常检查,督促做好全品种赋码激活与全链条扫码上传,做到”应赋尽赋、应扫尽扫”。对不落实法规规定、不符合追溯工作要求的,依照《药品管理法》《药品经营和使用质量监督管理办法》《药品经营质量管理规范》等严肃处理。公告强调”三医协同”(药监、医保、卫健),依托大数据智慧监管,提升风险发现与处置能力。数据安全要求明确:系统运营单位须依《数据安全法》建立数据安全管理制度。

对外资药企的意义

  • 追溯合规进入执法阶段,不再是”项目”。 进口制剂的外国持有人必须确保其境内责任人在国家平台完整运行赋码与上传闭环。境内责任人是持有人监管职能的延伸;责任人履职不力将直接拖累持有人整体在华合规态势。
  • 多码关联影响包装与IT工作。 标识码、商品条码、本位码、医保编码的关联意味着包装数据与ERP系统须在首次进口前与中国监管标识体系对齐。已带GS1条码的进口产品仍需完成中文标识码关联。
  • 合规玩家的渠道秩序改善。 “已在别处售出即拒收”与”异常预警即停售”直击回流药与串换编码乱象——这些乱象侵蚀合法定价体系。灰色渠道收窄,合规进口商受益。
  • 分销网络需具备GSP级文档能力。 分销商出入库扫码与质量负责人对异常预警的签字成为审计证据;外企应核实中国分销商系统确实能生成此类记录。
  • 与医保结算联动。 追溯与依码结算政策协同,扫码核验日益与报销、基金稽查挂钩;追溯数据不健全的产品在医院与医保渠道的报销可能受阻。

实务建议

  • 确认每个进口上市许可持有人的境内责任人在国家追溯协同平台登记有效,且每个在售SKU多码关联正确。
  • 审计包装与标签项目,确保追溯码、条码与层级关联在首次进入中国市场前完备。
  • 修订经销商合同,要求GSP合规的出入库扫码、异常预警处理与质量负责人签字记录。
  • 将内部ERP/质量系统与国家平台数据上传要求对齐,包括及时处理下游异常码反馈。
  • 跟踪省级执法动态与待出台的中药饮片追溯规则,并关注集采挂网与医院渠道中追溯与医保结算的衔接。

来源

  • 国家药监局 — 国家药监局关于进一步加强药品信息化追溯管理工作的公告(2026年第85号): https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260901134430105.html
  • 医药网 — 药品追溯新规出台 压实全产业链主体监管责任: https://news.pharmnet.com.cn/news/2026/09/02/625299.html
  • 央视新闻(辽宁药监转载)— 视频丨国家药监局:药品追溯须覆盖全品种全链条: https://www.toutiao.com/article/7681111672232100387

相关阅读

  • 见:外国持证人的药品进口许可与GSP义务(drug-import-licensing-gsp)
  • 见:医疗器械UDI分批强制与”药械同追”议程(medical-device-udi)

Beijing links its FTZ policy pool to 11 zones outside the fence: the FTZ Linkage Development Zones Work Plan

  • In late August / early September 2026, Beijing’s “Two Zones” (Beijing FTZ + national comprehensive demonstration zone for further opening of the services sector) leading group printed and distributed the Work Plan on Building the Beijing FTZ Linkage Development Zones (document 两区〔2026〕1号, dated 6 August 2026).
    2026年8月底至9月初,”两区”工作领导小组印发《中国(北京)自由贸易试验区联动发展区建设工作方案》(两区〔2026〕1号,成文日期2026年8月6日),对外发布。
  • The Plan designates 11 linkage development zones with a total area of 119.20 square kilometres across seven districts hosting FTZ clusters (Haidian, Changping, Chaoyang, Shunyi, Tongzhou, Daxing, E-Town) and four further districts (Fengtai, Shijingshan, Mentougou, Huairou), anchored on four industries: medicine & health, artificial intelligence, integrated circuits and commercial aerospace.
    方案确定11个联动发展区、总面积119.20平方公里,覆盖海淀、昌平、朝阳、顺义、通州、大兴、亦庄七个自贸组团所在区及丰台、石景山、门头沟、怀柔四区,聚焦医药健康、人工智能、集成电路、商业航天四大产业。
  • The design is an “industry + region” linkage system: rather than replicating FTZ policies everywhere, each linkage zone is paired with specific FTZ clusters so that policy strengths (e.g. data cross-border flows, stem-cell and gene-therapy opening, biomedical special-items customs clearance) can spill over to businesses located outside the FTZ.
    方案首创”产业+区域”联动体系:并非在各地复制自贸政策,而是让各联动区与特定自贸组团结对,使数据跨境流动、干细胞与基因诊疗技术开发应用开放、生物医药特殊物品通关等政策红利外溢到区外企业。
  • For medicine & health, the Plan builds a “Changping R&D and pilot-testing — E-Town, Daxing and Mentougou manufacturing — Tongzhou medical-industry synergy — Huairou enablement and innovation validation — Shunyi trade circulation” chain, sharing review-and-approval, cross-border finance, foreign-related legal and IP services.
    医药健康领域构建”昌平研发中试—亦庄、大兴、门头沟智造—通州医产协同—怀柔赋能及创新验证—顺义贸易流通”联动体系,共享审评审批、跨境金融、涉外法律、知识产权等服务。
  • For foreign investors, the linkage zones are a location-strategy signal: companies in life sciences, AI, chips and aerospace that need Beijing FTZ-type openness but do not want to locate inside the FTZ now have a formal mechanism to tap the same policy pool, with zone-level co-ordination bodies to follow.
    对外资投资者而言,联动发展区是一个选址信号:需要北京自贸区式开放、又不愿把实体落在自贸区内的生命科学、人工智能、芯片与航天企业,如今有了接入同一政策池的正式机制,后续将建立区级协调机构。

Beijing links its FTZ policy pool to 11 zones outside the fence: the FTZ Linkage Development Zones Work Plan | 北京”政策破墙”:11个自贸联动发展区如何把自贸红利带给区外企业

Overview

In early September 2026, Beijing publicised the Work Plan on Building the China (Beijing) Pilot Free Trade Zone Linkage Development Zones (《中国(北京)自由贸易试验区联动发展区建设工作方案》), a document of the “Two Zones” leading group (两区〔2026〕1号, dated 6 August 2026). The Plan responds to a concrete problem: companies inside the Beijing FTZ enjoy institutional openness — data cross-border flows, opening of stem-cell and gene-therapy technology development and application, and customs facilitation for special biomedical items — while companies immediately outside, which often form the same industrial chain, do not. Rather than expanding the FTZ’s physical border, Beijing is building a linkage mechanism so that FTZ policy strengths spill over to chosen zones outside it.

The “industry + region” design

The Plan selects four industries with international competitiveness as the anchor: the trillion-yuan-class medicine & health sector, the hundred-billion-yuan-class AI and integrated-circuit sectors, and the future-industry commercial aerospace sector. It then defines 11 linkage development zones covering 119.20 square kilometres:

  • the seven districts that host FTZ clusters — Haidian, Changping, Chaoyang, Shunyi, Tongzhou, Daxing and E-Town (亦庄/Beijing Economic-Technological Development Area); and
  • four further districts — Fengtai, Shijingshan, Mentougou and Huairou.

Zones were chosen on the principles of “sound industrial base, strong policy demand, clear spatial boundaries and workable management mechanisms”. The core working method is institutional docking (制度对接), industrial interconnection (产业互联) and platform integration (平台融通) between the FTZ clusters and the linkage zones.

Four industry chains

Medicine & health. Anchored on the Changping and E-Town clusters with Shunyi as the trade hub, the Plan builds the chain “Changping R&D and pilot-testing — E-Town, Daxing and Mentougou intelligent manufacturing — Tongzhou medical-industry synergy — Huairou enablement and innovation validation — Shunyi trade circulation“. Concretely:

  • Changping linkage zone co-operates on R&D and pilot-testing for medicine & health and synthetic biology;
  • E-Town linkage zone handles commercialisation of science results and industrialisation co-ordination;
  • Daxing linkage zone shares drug and device manufacturing and review-and-approval resources;
  • Mentougou linkage zone provides cardiovascular innovative drug-device R&D and smart-manufacturing resources;
  • Tongzhou linkage zone deepens medical-industry integration;
  • Huairou linkage zone supplies basic research and validation-and-transformation support.

The Plan also calls for joint breakthroughs on core technology bottlenecks in innovative drugs, synthetic biology and high-end medical devices; shared laboratories, medical-device prototype workshops, large-science facilities and pilot bases; and shared services in review and approval, cross-border finance, foreign-related law and IP.

Artificial intelligence. Anchored on Haidian and E-Town, the chain runs “Haidian original innovation — Shijingshan humanoid-robot training — Shunyi intelligent-driving vehicle R&D — E-Town, Chaoyang, Fengtai and Mentougou application — Mentougou computing power”, with shared computing resources, a co-ordinated AI computing-power scheduling platform, high-quality industry datasets and intelligent annotation platforms.

Integrated circuits. The chain runs “Haidian design — E-Town and Shunyi manufacturing — Chaoyang optoelectronics — Huairou original innovation and testing”, with industry-university-research innovation consortia, expanded advanced-process chip supply, and shared hardware-emulation, testing-validation and optoelectronic-packaging platforms.

Commercial aerospace. The chain runs “Haidian constellation R&D — Fengtai satellite application services — E-Town rocket R&D — Shijingshan deep-space exploration”, with result-transformation and supply-demand matching mechanisms and shared public services for test validation, pilot transformation and prototype manufacturing.

Why the linkage zones exist

Beijing’s “Two Zones” office explains the motivation in three layers:

  • Beijing FTZ enterprises need partners outside the FTZ for R&D innovation, high-end equipment, public platforms and application scenarios;
  • companies outside the FTZ have strong demand for FTZ-type policies — data cross-border flows, openness of stem-cell and gene-therapy technology development and application, and customs clearance of special biomedical items;
  • the linkage zones serve as Beijing’s own higher-level autonomous opening, implementing the central document on upgrading the free-trade-pilot-zone strategy.

The result is a systematic answer to a common complaint of foreign and domestic high-tech firms: “the policy is across the street but not for us”.

What this means for investors

  • A formal route to FTZ-type policy without FTZ location. Companies that anchor R&D or manufacturing in Haidian, Daxing, Mentougou, Huairou and other linkage zones can expect the same review-and-approval, cross-border data and customs facilitation agenda to be extended through zone-level co-ordination — worth verifying case by case with the relevant district.
  • Life-sciences value chain re-mapping. The medicine & health chain maps clear roles: R&D and pilot-testing in Changping, manufacturing in E-Town/Daxing/Mentougou, medical-industry synergy in Tongzhou, validation support in Huairou, trade in Shunyi. Foreign drug and device firms planning Beijing operations can now choose a site by chain position rather than by proximity alone.
  • AI and chip players should watch computing and dataset platforms. Shared AI computing-power scheduling and industry-dataset/annotation platforms imply subsidised or co-ordinated infrastructure; firms whose work is compute-heavy should evaluate Mentougou and the co-ordination platforms.
  • Implementation pace will be district-specific. The Plan is framework-level; each linkage zone is expected to develop concrete implementation measures, project pipelines and service packages. Early movers engaging district authorities now may shape those packages.

Practical steps

  • Map your Beijing operations against the four chains to identify which linkage zone matches your activity.
  • Approach the relevant district’s “Two Zones” office to confirm which FTZ policy items have been (or will be) extended to the linkage zone and through which procedures.
  • For biomedical firms, review the stem-cell/gene-therapy and special-items customs facilitation pipeline, and whether your planned site can access the shared review-and-approval services.
  • For AI/chip firms, evaluate the shared computing, dataset and testing platforms as location or co-operation options.
  • Track each linkage zone’s implementation measures as they are released during late 2026.

Sources

  • 北京市人民政府门户网站 — “两区”工作领导小组关于印发《中国(北京)自由贸易试验区联动发展区建设工作方案》的通知(两区〔2026〕1号): https://www.beijing.gov.cn/zhengce/zhengcefagui/202609/t20260904_4850659.html
  • 北京市商务局 — 《中国(北京)自由贸易试验区联动发展区建设工作方案》政策解读: https://sw.beijing.gov.cn/zwxx/2024zcjd/202609/t20260904_4850606.html
  • 央视网 — 设立11个自贸试验区联动发展区 协同布局四大重点产业: https://city.news.cctv.com/2026/09/01/ARTIsH2heuLNbNftPbkl2M9b260901.shtml
  • 人民网北京频道 — 北京划定11个自由贸易试验区联动发展区: https://bj.people.com.cn/n2/2026/0904/c14540-41686517.html

Related reading

  • see also: how FTZ setups work and typical incentives for foreign investors (ftz-setup-basics)
  • see also: Beijing’s services-sector opening and “Two Zones” agenda (beijing-two-zones-opening)

北京”政策破墙”:11个自贸联动发展区如何把自贸红利带给区外企业

概述

2026年9月初,北京对外发布《中国(北京)自由贸易试验区联动发展区建设工作方案》(两区〔2026〕1号,成文日期2026年8月6日)。方案回应一个具体难题:北京自贸区内企业享有制度型开放——数据跨境流动、干细胞与基因诊疗技术开发应用开放、生物医药特殊物品通关便利——而仅一街之隔、往往同处一条产业链的区外企业却享受不到。北京的选择不是扩大自贸区物理边界,而是建立联动机制,让自贸政策红利外溢到精选的区外区域。

“产业+区域”的设计

方案筛选出四大具有国际竞争力的产业作为联动核心:万亿级的医药健康、千亿级的人工智能与集成电路、未来产业的商业航天。据此确定11个联动发展区,总面积119.20平方公里:

  • 7个自贸组团所在区——海淀、昌平、朝阳、顺义、通州、大兴、亦庄;
  • 4个其他区——丰台、石景山、门头沟、怀柔。

选区的原则是”产业基础好、政策诉求强、空间边界清、管理机制顺”。核心工作方法是自贸组团与联动区之间的制度对接、产业互联、平台融通。

四条产业链

医药健康。 以昌平组团、亦庄组团为基点,顺义组团为枢纽,构建”昌平研发中试—亦庄、大兴、门头沟智造—通州医产协同—怀柔赋能及创新验证—顺义贸易流通“联动体系。具体分工:

  • 昌平联动区协同开展医药健康与合成生物产业研发中试;
  • 亦庄联动区承接科技成果落地与产业化协作;
  • 大兴联动区共享药品药械制造、审评审批资源;
  • 门头沟联动区提供心血管创新药械研发智造资源;
  • 通州联动区深化医产融合发展;
  • 怀柔联动区提供基础研究与验证转化支撑。

方案要求围绕创新药、合成生物、高端医疗器械开展协同攻关,共享实验室、医疗器械样机制作平台、大科学装置、中试基地,并提供审评审批、跨境金融、涉外法律、知识产权等服务。

人工智能。 以海淀组团、亦庄组团为基点,构建”海淀策源—石景山人形机器人训练—顺义智能驾驶汽车研发—亦庄、朝阳、丰台、门头沟应用—门头沟算力”联动体系,共享算力资源与平台设施,共建人工智能算力资源协同调度平台、高质量行业数据集和智能化标注平台。

集成电路。 构建”海淀设计—亦庄、顺义制造—朝阳光电—怀柔原始创新及测试”联动体系,组建产学研创新联合体,提升先进制程芯片规模化供给能力,共享公共硬件仿真平台、集成电路测试验证平台、光电芯片封装测试验证平台。

商业航天。 构建”海淀星座研发—丰台卫星应用服务—亦庄火箭研发—石景山深空探测”联动体系,建立研发成果转化与供需对接机制,共享试验验证、中试转化、打样制造等全链条公共服务。

为什么要设联动发展区

北京”两区”工作领导小组办公室从三个层面解释动因:

  • 自贸区内企业在研发创新攻坚、高端设备配套、公共平台共享、应用场景拓展上需要与区外企业协作;
  • 区外企业对数据跨境流动、干细胞与基因诊疗技术开发和应用开放、生物医药特殊物品通关等政策需求强烈;
  • 设立联动区是落实《中共中央、国务院关于实施自由贸易试验区提升战略的意见》、服务全产业链创新发展、探索更高水平自主开放的重要抓手。

方案系统回应了内外资高科技企业的常见抱怨:”政策就在街对面,但不适用于我们。”

对投资者的意义

  • 不落自贸区也能接入自贸政策池的正式通道。 把研发或制造布局在海淀、大兴、门头沟、怀柔等联动区的企业,可望通过区级协调获得与自贸区同向的审评审批、跨境数据与通关便利——具体条目与程序需与所在区逐一核实。
  • 生命科学价值链重新布局。 医药健康链的角色划分清晰:昌平做研发中试、亦庄/大兴/门头沟做智造、通州做医产协同、怀柔做验证支撑、顺义做贸易。计划布局北京的外资药械企业可按链上位置选址,而非只看远近。
  • AI与芯片企业应关注算力与数据平台。 共享算力调度、行业数据集与标注平台意味着有组织的基础设施供给;算力密集型企业应评估门头沟及协同平台。
  • 落地节奏因区而异。 方案是框架性的;各联动区将出台具体实施办法、项目清单与服务包。现在与区级部门接洽的先行者可能影响这些配套的成型。

实务建议

  • 对照四条产业链梳理自身北京业务,判断匹配哪个联动区。
  • 联系所在区”两区”办,确认哪些自贸政策条目已(或将)延伸到联动区、通过何种程序。
  • 生物医药企业核查干细胞/基因治疗与特殊物品通关便利管线,确认计划选址能否接入共享审评审批服务。
  • AI与芯片企业把共享算力、数据集与测试平台作为选址或合作选项评估。
  • 跟踪2026年下半年各联动区陆续发布的实施办法。

来源

  • 北京市人民政府门户网站 — “两区”工作领导小组关于印发《中国(北京)自由贸易试验区联动发展区建设工作方案》的通知(两区〔2026〕1号): https://www.beijing.gov.cn/zhengce/zhengcefagui/202609/t20260904_4850659.html
  • 北京市商务局 — 《中国(北京)自由贸易试验区联动发展区建设工作方案》政策解读: https://sw.beijing.gov.cn/zwxx/2024zcjd/202609/t20260904_4850606.html
  • 央视网 — 设立11个自贸试验区联动发展区 协同布局四大重点产业: https://city.news.cctv.com/2026/09/01/ARTIsH2heuLNbNftPbkl2M9b260901.shtml
  • 人民网北京频道 — 北京划定11个自由贸易试验区联动发展区: https://bj.people.com.cn/n2/2026/0904/c14540-41686517.html

相关阅读

  • 见:自贸区落地机制与外资企业典型激励(ftz-setup-basics)
  • 见:北京服务业扩大开放与”两区”议程(beijing-two-zones-opening)

Declaring psychotropic drug imports and exports: NMPA-GACC Announcement 2026 No. 84

  • The National Medical Products Administration (NMPA) and the General Administration of Customs (GACC) jointly published Announcement 2026 No. 84 on 28 August 2026, providing the customs HS commodity numbers to reference when declaring import or export of newly controlled medicinal psychotropic substances.
    2026年8月28日,国家药监局与海关总署联合发布2026年第84号公告,就新列入管制范围的药用类精神药品的进出口申报,公布供通关申报参考的海关商品编号。
  • The announcement follows a separate joint decision by NMPA, the Ministry of Public Security and the National Health Commission adding three substances to the medicinal psychotropic substance catalogue: methoxyetomidate, leretomidate and sonanfetomide — with exceptions for drug preparations approved for marketing in China.
    公告之前,国家药监局、公安部、国家卫生健康委联合发布调整公告,将甲氧依托咪酯、乐瑞托咪酯、索安非托增列入药用类精神药品目录(在中国境内批准上市的相应药品制剂除外)。
  • The published commodity numbers cover only part of the controlled goods; importers and exporters whose actual goods fall outside the listed numbers must declare truthfully rather than assume exemption.
    公布的编号仅包含管制商品中的部分商品;实际进出口商品超出相关商品编号范围的,应当如实申报,而非推定不涉管制。
  • The rules anchor to the Drug Administration Law and the Customs Law: medicinal psychotropic substances remain subject to import/export permit and reporting disciplines administered by NMPA and customs.
    新规以《药品管理法》《海关法》为法律依据:药用类精神药品进出口仍适用由国家药监局与海关管理的准许证与申报纪律。
  • The announcement takes effect on 1 October 2026, giving pharmaceutical importers, exporters and CRO/logistics partners a one-month window to update screening and declaration procedures.
    公告自2026年10月1日起施行,为医药进出口企业、研发外包与物流伙伴留下约一个月时间更新筛查与申报流程。
  • For pharmaceutical companies shipping controlled APIs or finished drugs in or out of China, the practical task is to verify each SKU against the expanded catalogue and the new commodity numbers, and to keep records showing the actual substance and formulation status.
    对进出境受管制原料药或制剂的企业而言,实操要点是逐一核对产品品目是否落入扩围后的目录与新商品编号,并留存能证明实际物质与制剂状态的记录。

Declaring psychotropic drug imports and exports: NMPA-GACC Announcement 2026 No. 84 | 药用类精神药品进出口申报新规:国家药监局 海关总署2026年第84号公告解读

Overview

On 28 August 2026 the National Medical Products Administration (NMPA) and the General Administration of Customs (GACC) published Announcement 2026 No. 84 — Matters Concerning the Declaration of Import and Export of Medicinal Psychotropic Substances (国家药监局 海关总署关于药用类精神药品进出口申报事项的公告). The announcement sets out the customs HS commodity numbers to reference when declaring imports or exports of varieties that were recently added to the medicinal psychotropic substance catalogue, and takes effect on 1 October 2026.

The announcement sits on top of an earlier regulatory step: NMPA, the Ministry of Public Security and the National Health Commission jointly issued a decision adjusting the medicinal psychotropic substance catalogue, adding methoxyetomidate, leretomidate and sonanfetomide to the list — except for drug preparations containing these substances that have been approved for marketing in China. Announcement 2026 No. 84 was then issued under the Drug Administration Law and the Customs Law to give traders concrete reference numbers for customs declaration.

Why this matters

China exercises strict control over psychotropic substances under its drug-control system, and the import and export of such substances requires permits and compliant declaration. The significance of this announcement is twofold:

  1. The control scope just widened. Three substances — methoxyetomidate, leretomidate and sonanfetomide — have been added to the medicinal psychotropic substance catalogue. Any company shipping these substances into or out of China (outside the China-approved formulation carve-out) now falls within the controlled-substance regime.
  2. Customs now has published reference codes. By giving HS commodity numbers for the newly added varieties, NMPA and GACC intend to reduce ambiguity at the border so that declarations are consistent and shipments are not held up by classification disputes.

The key provisions

  • Reference commodity numbers. The announcement publishes the customs commodity numbers for the newly listed varieties, for reference in customs declaration.
  • Partial coverage. The announcement expressly states that the commodity numbers cover only *part* of the controlled goods. If the actual goods being imported or exported fall outside the listed commodity-number range, the declarant must still declare truthfully.
  • Legal basis. The announcement is issued under the Drug Administration Law, the Customs Law and related laws and regulations.
  • Effective date. 1 October 2026.

The honest-declaration clause is the operative discipline: the commodity numbers are a facilitation tool, not a safe harbour. A shipment containing a newly controlled substance but classified under a different HS number remains subject to the controlled-substance rules, and the declarant bears the duty to reflect the true nature of the goods.

Context: the wider psychotropic-substance framework

Medicinal psychotropic substances are regulated separately from narcotic drugs but within the same family of controlled-substance rules. Imports and exports generally require permits issued through the drug-administration system, and customs releases goods against those permits together with normal declaration documents. Companies trading in active pharmaceutical ingredients (APIs) or finished drugs that touch the controlled list must:

  • verify whether each product contains a catalogue substance;
  • confirm whether a China-approved formulation exception applies;
  • obtain the appropriate permits before shipment; and
  • declare accurately at customs using the published reference codes where applicable.

What companies should do before 1 October 2026

For pharmaceutical importers and exporters — including foreign companies shipping APIs into China for contract manufacturing, or exporting controlled finished products — the practical checklist is:

  • Re-screen the product portfolio. Compare every SKU in the import/export pipeline against the expanded medicinal psychotropic catalogue, paying attention to the three new substances by both Chinese and international names.
  • Map the formulation exception. The catalogue addition excludes drug preparations approved for marketing in China. Confirm whether the product you ship is such an approved preparation and keep supporting registration documents in the compliance file.
  • Update declaration masters. Where a controlled substance is involved, update product masters, customs-classification records and the reference commodity numbers so that declarations after 1 October use the correct codes.
  • Check permit status. Confirm that the necessary import/export permits are in place and that the responsible internal or third-party declarant understands the split of duties between NMPA permits and customs release.
  • Prepare for audits. Regulators and customs may test whether declared goods match actual substance content. Retain certificates of analysis, formulation sheets and supply-chain records that demonstrate the true state of each shipment.
  • Brief logistics and CRO partners. If a third party handles declaration or cross-border logistics, circulate the announcement so screening updates are applied across the chain, not only at the licence holder.

Practical notes for foreign pharmaceutical companies

Foreign companies most affected are those that supply or buy the three newly controlled substances — or that manufacture medicines where these substances appear as intermediates or impurities above applicable thresholds. Points worth noting:

  • The announcement is a border-declaration facilitation measure; it does not by itself change the permit regime, which continues to apply to controlled substances.
  • The “approved formulation” carve-out is narrow: it protects drug preparations approved for marketing in China, not raw substances or unapproved preparations.
  • Given the 1 October effective date, any shipment booked for late September and arriving in October should be screened under the new scope to avoid a compliance gap.

Sources

  • 国家药品监督管理局 — 国家药监局 海关总署关于药用类精神药品进出口申报事项的公告(2026年第84号): https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260902092356142.html
  • 中华人民共和国海关总署 — 政务公告列表(含2026年第84号、第128号、第129号等): http://www.customs.gov.cn/
  • 医药魔方 — 药用类精神药品进出口申报事项公告(品种与施行日期摘要): https://bydrug.pharmcube.com/news/detail/484ba2600ed6d80d29192ad8ba49dca8

Related reading

  • see also: China’s 2026 customs clearance guide for the ninth CIIE (370-ciie-2026-customs-clearance-guide)
  • see also: Guangdong’s international medical services pilot and pharma investment (329-guangdong-international-medical-services)

药用类精神药品进出口申报新规:国家药监局 海关总署2026年第84号公告解读

概述

2026年8月28日,国家药品监督管理局与海关总署联合发布《关于药用类精神药品进出口申报事项的公告》(2026年第84号),就近期增列入药用类精神药品目录的品种,公布供进出口通关申报参考的海关商品编号。公告自2026年10月1日起施行。

公告建立在更早一步的监管动作之上:国家药监局、公安部、国家卫生健康委联合发布调整药用类精神药品目录的公告,将甲氧依托咪酯、乐瑞托咪酯、索安非托增列入药用类精神药品目录(在中国境内批准上市的含上述物质的药品制剂除外)。随后,依据《药品管理法》《海关法》等法律法规,2026年第84号公告出台,为贸易企业提供具体的通关申报参考编号。

为何重要

中国在药物管制体系下对精神药品实行严格管控,此类物质的进出口需取得准许证并合规申报。本次公告的意义有二:

  1. 管制范围刚刚扩大。 甲氧依托咪酯、乐瑞托咪酯、索安非托三个品种被增列入药用类精神药品目录。任何将上述物质运入或运出中国的企业(中国批准上市制剂除外),如今均落入管制物质制度范畴。
  2. 海关有了公开的参考编码。 通过为新增品种提供海关商品编号,国家药监局与海关总署意在减少口岸的归类不确定性,使申报口径一致,避免货物因归类争议而被滞留。

主要条款

  • 参考商品编号。 公告公布新增列品种的海关商品编号,供通关申报参考。
  • 部分覆盖。 公告明确,公布的编号仅包含管制商品中的部分商品。实际进出口商品超出相关商品编号范围的,仍应当如实申报。
  • 法律依据。 公告依据《药品管理法》《海关法》等法律法规制定。
  • 施行日期。 2026年10月1日。

“如实申报”条款是操作性纪律:商品编号是便利工具,而非安全港。一批含有新管制物质但归入其他HS编码的货物,仍适用管制物质规则,申报人有义务如实反映货物的真实属性。

背景:更宽的精神药品监管框架

药用类精神药品与麻醉药品分列管制,但同属管制物质规则体系。其进出口一般需通过药监系统取得准许证,海关凭准许证及常规申报文件放行。经营涉及管制清单的原料药或制剂的贸易企业,必须:

  • 核实每个产品是否含有目录内物质;
  • 确认是否适用”中国批准上市制剂”例外;
  • 在发货前取得相应准许证;
  • 在口岸按公布的参考编码如实准确申报。

2026年10月1日前应做的事

对医药进出口企业——包括向中国境内合同生产方供应原料药、或出口受管制成品的外国公司——实用核查清单如下:

  • 重新筛查产品组合。 将进出境管线中的每个品目与扩围后的药用类精神药品目录逐一比对,重点关注三个新增品种(中英文名称均需核对)。
  • 核实制剂例外。 目录增列不包含在中国境内批准上市的药品制剂。请确认你所运产品是否属于此类获批制剂,并在合规档案中留存注册证明文件。
  • 更新申报主数据。 若涉及管制物质,更新产品主数据、海关归类记录与参考商品编号,确保10月1日后的申报使用正确编码。
  • 核查准许证状态。 确认必要的进出口准许证已就位,并让内部或第三方申报人清楚理解药监准许证与海关放行之间的职责分工。
  • 备妥审计材料。 监管部门与海关可能核查申报货物与实际物质含量是否一致。留存检验报告、制剂配方单与供应链记录,以证明每批货物的真实状态。
  • 同步物流与外包伙伴。 若由第三方代理申报或负责跨境物流,应转发公告,使筛查更新贯穿整个链条,而不只停留在持证人一端。

给外国药企的实务提示

受影响最大的外国公司,是那些供应或采购上述三种新管制物质的企业,或在其药品中将此类物质作为中间体、杂质(超过适用阈值)出现的企业。值得注意:

  • 本公告属口岸申报便利化措施,本身并不改变准许证制度,管制物质仍须适用该制度。
  • “批准制剂”例外范围较窄:它保护在中国获批上市的药品制剂,不涵盖原料物质或未获批制剂。
  • 鉴于10月1日生效,凡9月下旬订舱、10月到港的货物,都应按新范围筛查,避免出现合规空档。

来源

  • 国家药品监督管理局 — 国家药监局 海关总署关于药用类精神药品进出口申报事项的公告(2026年第84号): https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20260902092356142.html
  • 中华人民共和国海关总署 — 政务公告列表(含2026年第84号、第128号、第129号等): http://www.customs.gov.cn/
  • 医药魔方 — 药用类精神药品进出口申报事项公告(品种与施行日期摘要): https://bydrug.pharmcube.com/news/detail/484ba2600ed6d80d29192ad8ba49dca8

相关阅读

  • 见:第九届进博会海关通关须知(370-ciie-2026-customs-clearance-guide)
  • 见:广东国际医疗服务试点与医药投资(329-guangdong-international-medical-services)

Dalian’s Services-Opening Pilot Goes Operational: Medical Access Guides and the Implementation Plan

  • In August 2026 Dalian stepped up its services-opening pilot: the municipal commerce bureau opened a 7-day public comment on the Dalian Implementation Plan for the Services Industry Expansion and Opening Comprehensive Pilot (draft), while the municipal health commission issued three compliance guides for foreign doctors opening clinics, foreign-invested non-profit medical institutions and short-term practice by overseas physicians.
    2026 年 8 月,大连加码服务业扩大开放试点:市商务局对《大连市服务业扩大开放综合试点实施方案(草案)》公开征求意见(7 天);市卫生健康委发布三项合规办事指引,覆盖外籍及港澳台医生开设诊所、中外合资合作非营利性医疗机构、境外医师短期执业。
  • Dalian is one of nine cities — together with Ningbo, Xiamen, Qingdao, Shenzhen, Hefei, Fuzhou, Xi’an and Suzhou — added to the national services-opening pilot in 2025, carrying 159 pilot tasks assigned by the Ministry of Commerce in January 2026.
    大连是 2025 年新增的 9 个服务业扩大开放综合试点城市之一(另有宁波、厦门、青岛、深圳、合肥、福州、西安、苏州),承接商务部 2026 年 1 月赋予的 159 项试点任务。
  • The medical guides convert national pilot tasks into standardised filing procedures: clear legal bases, applicant conditions, document checklists and process steps for overseas medical professionals and institutions to practise or establish entities in Dalian.
    医疗三项指引把国家试点任务转化为标准化审批办事规范:明确境外医疗人才、机构来连执业办医的办理依据、申请条件、申报材料与办理流程。
  • The pilot tasks cover telecom services, healthcare, business, culture and tourism and finance, with each city encouraged to design distinctive tasks based on local strengths — Dalian’s health-sector focus reflects its industrial base.
    试点任务覆盖电信服务、医疗康养、商贸文旅、金融等重点领域,鼓励各城市结合自身优势设计个性化任务——大连聚焦医疗审批改革与其产业基础契合。
  • For foreign healthcare providers, the practical entry point is clear: use the three Dalian guides to prepare clinic-licensing or short-term-practice filings, and watch the city’s implementation plan for wider services-opening commitments.
    对外资医疗机构与境外医师,实操入口明确:按大连三项指引准备诊所设置或短期执业申报,并关注该市实施方案中的更广开放承诺。

Dalian’s Services-Opening Pilot Goes Operational: Medical Access Guides and the Implementation Plan | 大连服务业扩大开放试点落地:医疗开放指引与实施方案

From national pilot to city-level rules

Dalian was one of nine cities added to the national services industry expansion and opening comprehensive pilot in 2025 — together with Ningbo, Xiamen, Qingdao, Shenzhen, Hefei, Fuzhou, Xi’an and Suzhou — bringing the pilot network to 20 cities. In January 2026 the Ministry of Commerce issued the pilot tasks for these nine cities: 159 tasks spanning telecom services, medical and healthcare, business, culture and tourism, and finance, with a “common plus distinctive” structure that lets each city combine national commitments with locally tailored measures. In August 2026 Dalian translated this national framework into local, operational rules. On 20 August the municipal commerce bureau published the Dalian Implementation Plan for the Services Industry Expansion and Opening Comprehensive Pilot (draft) for a seven-day public comment period. Days earlier, the municipal health commission released three compliance guides covering the healthcare tasks.

The three medical compliance guides

The three guides issued by the Dalian health commission are: (1) the Compliance Guide for Foreign and Hong Kong, Macao and Taiwan Doctors Opening Clinics in Dalian; (2) the Compliance Guide for Applying to Establish Sino-foreign Jointly Invested or Co-operated Non-Profit Medical Institutions in Dalian; and (3) the Compliance Guide for Overseas Physicians Conducting Short-Term Practice in Accordance with Regulations in Dalian. Each guide standardises the approval chain end to end: the legal basis, applicant conditions, required documents and the filing process, converting national pilot tasks into the day-to-day norms that local regulators will apply. The three areas covered — foreign doctors’ clinics, short-term practice by overseas physicians and non-profit joint medical institutions — correspond exactly to the tasks the national pilot assigns to the healthcare sector.

What the draft implementation plan signals

The draft implementation plan, open for comment until 26 August, sets out how Dalian will implement the 159 tasks more broadly. It is grounded in the MOFCOM notice on the nine-city pilot tasks (Shang Zi Han [2026] No. 5) and, once finalised, will be the reference document for foreign investors assessing Dalian’s services sector. Combined with the medical guides, it signals that Dalian intends to be a practical testbed: national policy is being converted into city-level processes that businesses can follow, rather than left as abstract commitments.

Why it matters for foreign healthcare and services investors

For foreign healthcare providers, the package matters for three reasons. First, entry clarity: the three guides specify exactly what an overseas physician needs to open a clinic or practise short-term in Dalian — reducing the uncertainty that historically surrounded medical licensing for foreign professionals. Second, breadth: the implementation plan, once final, will clarify Dalian’s approach to telecom, business, culture and tourism and finance tasks, helping investors see the full opening landscape rather than a single sector. Third, precedent value: Dalian is among the first of the nine 2025-vintage pilot cities to convert its tasks into published compliance guides, so the format is likely to be imitated by other cities — making the Dalian documents useful templates for understanding how services opening is being operationalised across China.

Practical steps

Foreign investors and medical professionals should: (1) review the three health-commission guides against their specific plans — clinic establishment, short-term practice or a non-profit joint institution — and assemble the document package each guide lists; (2) engage the Dalian health commission early on applicant qualifications, since foreign-doctor clinic rules require careful checking of professional credentials and prior practice records; (3) track the finalised version of the implementation plan through the Dalian commerce bureau for wider services commitments; and (4) for investors comparing Chinese cities, treat Dalian’s published guides as one example of how the nine-city pilot tasks are being implemented, and benchmark against the progress of peer cities such as Fuzhou, Shenzhen and Xi’an.

The wider context: services opening as a national agenda

Dalian’s package sits inside a broader national push that foreign investors should read as a trend, not a one-off. The “15th Five-Year Plan” outline treats services as the main front of opening: expanding market access in telecom, internet, education, culture and healthcare, and steadily running the value-added telecom, biotech and wholly foreign-owned hospital pilots. Two negative lists are the operational instruments — the foreign-investment negative list and the cross-border services trade negative list — and pilot FTZs and services-opening pilot cities are the testbeds. For a foreign services provider, the practical implication is that city-level documents like Dalian’s implementation plan and compliance guides are where national commitments become enforceable processes; monitoring them is the difference between reading about opening and actually entering a market. The same mechanics — a national task, a local implementation plan, sector-specific compliance guides — are being replicated across the nine new pilot cities, so a company that understands Dalian’s format can apply the same analytical lens to Fuzhou, Shenzhen, Qingdao and the rest.

Sources


大连服务业扩大开放试点落地:医疗开放指引与实施方案

从国家试点到市级规则

大连是 2025 年新增的 9 个服务业扩大开放综合试点城市之一(另有宁波、厦门、青岛、深圳、合肥、福州、西安、苏州),试点网络由此扩围至 20 城。2026 年 1 月,商务部印发 9 城市服务业扩大开放综合试点任务:159 项任务覆盖电信服务、医疗康养、商贸文旅、金融等领域,采用”共性+个性”结构,鼓励各城市把国家承诺与本地特色结合。2026 年 8 月,大连将国家框架转化为本地操作性规则。8 月 20 日,市商务局发布《大连市服务业扩大开放综合试点实施方案(草案)》并公开征求意见(7 天);此前数日,市卫生健康委发布覆盖医疗领域试点任务的三项合规办事指引。

三项医疗合规指引

大连市卫健委发布的三项指引为:(1)《大连市外籍及港澳台医生开设诊所合规办事指引》;(2)《大连市申办中外合资、合作非营利性医疗机构合规办事指引》;(3)《大连市境外医师按规定从事短期执业活动合规办事指引》。每项指引对审批链条做全流程标准化:办理依据、申请条件、申报材料、办理流程,把国家试点任务转化为地方监管日常适用的规范。三个覆盖领域——外籍医生诊所、境外医师短期执业、中外合资非营利性医疗机构——与全国试点赋予医疗行业的任务一一对应。

实施方案草案的信号

实施方案草案(征求意见截止 8 月 26 日)明确大连将如何更广地落实 159 项任务。文件依据商务部 9 城市试点任务通知(商资函〔2026〕5 号)制定,定稿后将成为外资投资者评估大连服务业的参考文件。与医疗指引结合,方案传递的信号是:大连要做实操试验田——国家政策被转化为企业可遵循的城市级流程,而非停留在抽象承诺。

对外资医疗与服务投资者的意义

对外资医疗机构,这一揽子安排有三重意义。第一,准入清晰:三项指引精确说明境外医师在大连开设诊所或短期执业需要什么,降低了外籍医疗执业许可长期以来的不确定性。第二,广度:实施方案定稿后将明确大连对电信、商贸、文旅、金融任务的态度,投资者可见全貌而非单一行业。第三,先例价值:大连是 2025 年批次 9 城市中率先把试点任务转化为公开合规指引的城市之一,格式很可能被其他城市效仿——大连文件因此成为理解全国服务业开放如何落地化的有用模板。

操作建议

外资投资者与境外医疗专业人士应:(1)对照三项指引核对自己的具体计划——开设诊所、短期执业或非营利性合资机构——并按指引清单准备材料包;(2)尽早与大连市卫健委沟通申请人资质,外籍医生诊所规则对执业资格与既往执业记录核对要求细致;(3)通过市商务局跟踪实施方案定稿版,获取更广服务承诺;(4)比较不同中国城市时,把大连的公开指引视为 9 城市试点任务落地的一个样本,并与福州、深圳、西安等同批城市进展对标。

更大背景:服务业开放作为国家议程

大连的一揽子安排处在一个更广的国家推进之中,外国投资者应视之为趋势而非一次性事件。”十五五”规划纲要视服务业为开放主战场:推动电信、互联网、教育、文化、医疗等领域有序扩大开放,稳妥实施增值电信、生物技术、外商独资医院等开放试点。两张负面清单是操作工具——外商投资准入负面清单与跨境服务贸易负面清单——自贸试验区与服务业扩大开放试点城市是试验田。对外资服务商,实际含义是:像大连实施方案与合规指引这样的城市级文件,正是国家承诺转化为可执行流程之处;跟踪它们是”读到开放”与”真正进入市场”的区别。同一机制——国家任务、地方实施方案、分行业合规指引——正在 9 个新增试点城市复制,理解了大连格式的企业可以把同样的分析框架套用于福州、深圳、青岛等城市。

Sources

Greater Bay Area 2026: foreign-investment opportunities in healthcare and cross-border medical services

  • The “Hong Kong/Macao medicine pass” (港澳药械通) had approved 162 innovative drugs and devices (71 drugs, 91 devices) across 71 designated hospitals in all nine GBA cities by late April 2026, serving over 17,000 patient-visits.
    截至 2026 年 4 月底,”港澳药械通”已在九市 71 家指定医院获批 162 款创新药械(71 药品、91 器械),惠及超 1.7 万人次。
  • A January 2026 multinational-pharma GBA roundtable in Guangzhou gathered 15 global firms (J&J, Pfizer, AstraZeneca, Bayer, Novartis, AbbVie, Sanofi) and highlighted GBA as a strategic channel for foreign innovators.
    2026 年 1 月广州举办的跨国药企大湾区行座谈会汇聚 15 家跨国药企(强生、辉瑞、阿斯利康、拜耳、诺华、艾伯维、赛诺菲),凸显大湾区作为外企创新战略通道的定位。
  • Real-world study (RWS) via the medicine pass lets foreign products enter GBA within roughly six months and build evidence for national registration.
    借药械通开展真实世界研究,可使外资产品约 6 个月内进入大湾区,并为全国注册积累证据。
  • Qianhai has issued the nation’s first policy supporting Hong Kong/Macao and foreign-invested medical institutions, with 14 international medical institutions and 4,045 beds clustered there.
    前海出台全国首个支持港澳及外商医疗机构集聚发展政策,已集聚 14 家国际化医疗机构、床位 4045 张。
  • The June 2026 “Action Plan for Stabilising and Optimising Foreign Investment” expands the wholly foreign-owned hospital pilot, already covering nine localities including Guangdong and Shenzhen.
    2026 年 6 月《利用外资固稳促优行动方案》扩大外商独资医院试点,该试点已覆盖含广东、深圳在内的 9 地。
  • Cross-boundary medical data and ambulance transfer are now operational, with Shenzhen–Hong Kong medical-data channels transmitting over 6.79 million files in four months.
    跨境医疗数据与转运已落地,深港医疗数据通道上线 4 个月传输超 679 万份文件。
  • Foreign investors should enter via the medicine pass for products, the FTZ hospital pilot for services, and RWS collaboration for evidence generation.
    外资企业应通过药械通导入产品、借自贸区医院试点提供医疗服务、以真实世界研究合作生成证据。

Greater Bay Area 2026: foreign-investment opportunities in healthcare and cross-border medical services | 2026 大湾区:医疗健康产业外资机会(港澳药械通、跨境医疗服务)

Overview

Healthcare is one of the most attractive — and most regulated — sectors for foreign investors in the Greater Bay Area (GBA). Two forces converge in 2026. First, the “Hong Kong/Macao medicine pass” (港澳药械通) has matured from a regional pilot into a strategic channel that multinational innovators treat as part of their China strategy. Second, the policy environment for foreign-invested medical services — wholly foreign-owned hospitals, Hong Kong/Macao-invested institutions, cross-boundary care — is being actively widened. For a foreign healthcare group, the GBA is no longer just a sales market but a place to run clinical evidence, pilot cross-boundary care and anchor regional operations.

This article maps the 2026 opportunity across three layers: innovative drugs and devices via the medicine pass, foreign-invested and Hong Kong/Macao medical institutions, and cross-boundary medical services and data.

The medicine pass: from pilot to strategic channel

The 2026 multinational-pharma GBA roundtable, held in Guangzhou on 28 January 2026 and hosted by the Guangdong Development Reform Commission (Provincial GBA Office), brought together leaders from 15 multinationals — Johnson & Johnson, Pfizer, AstraZeneca, Bayer, Novartis, AbbVie, Sanofi and others — with Guangdong and nine-city governments. The message from firms was consistent: the GBA’s market potential and innovation ecosystem make it a strategic location, and the medicine pass is the fastest route for innovative products.

The pass has expanded sharply. The number of Hong Kong/Macao drugs and devices approved for use in the GBA rose from 48 in 2023 to 146 (another source cites 149) by early 2026, and designated medical institutions grew from 19 to 71, covering all nine GBA cities. By late April 2026 the approved total reached 162 innovative products (71 drugs, 91 devices), serving over 17,000 patient-visits. Guangdong has enacted the *Regulations of Guangdong Province on the Import of Hong Kong and Macao Drugs and Medical Devices in the Nine GBA Mainland Cities*, standardising filing and approval and raising efficiency.

For foreign innovators the decisive advantage is speed and evidence. Industry experts note that, versus the traditional registration path, products can clear the medicine-pass access process in as little as six months. Just as important, the pass supports real-world study (RWS): Guangdong has issued supporting policies allowing public hospitals to collaborate with firms on RWS and detailing the filing process. Seven multinationals have already run nine RWS projects with four GBA medical institutions. A notable case is Pfizer’s migraine drug rimegepant, whose prospective single-arm multi-centre RWS was completed in three months using Guangzhou’s rich clinical resources.

Foreign-invested and Hong Kong/Macao medical institutions

On the services side, Qianhai has issued what it describes as the nation’s first policy supporting the clustered development of Hong Kong/Macao and foreign-invested medical institutions, and is advancing a wholly foreign-owned hospital pilot. The cluster already comprises 14 international medical institutions with 4,045 beds, and overseas-patient visits grow over 10% annually. Under “talent connect”, Shenzhen’s first Hong Kong nurse registered to practise in Qianhai, six Hong Kong-style family-doctor studios opened, and 44 overseas medical experts are resident. Under “medicine connect”, the pass covers five tertiary hospitals in the cooperation zone with 60 approved items serving over 2,300 patient-visits. Under “ambulance connect”, cross-boundary transfer achieves “no-exit clearance, point-to-point direct” with transfer time cut by 80%.

The June 2026 *Action Plan for Stabilising and Optimising Foreign Investment* (MOFCOM, NDRC, MOF) explicitly supports studying and expanding the geographic scope of the wholly foreign-owned hospital pilot. The existing pilot covers nine localities — Beijing, Shanghai, Tianjin, Nanjing, Suzhou, Fuzhou, Guangdong, Shenzhen and the whole of Hainan island — and the plan signals further expansion. It also supports bringing more innovative drugs and devices into commercial insurance coverage and facilitating foreign-invested drugs into retail channels.

Cross-boundary medical services and data

Cross-boundary care is becoming operational. The University of Hong Kong–Shenzhen Hospital — a GBA cross-boundary medical benchmark — is among the first medicine-pass pilot hospitals, has introduced 34 international drugs and 18 devices serving over 7,500 patient-visits, and hosts nearly 100 Hong Kong-registered doctors. It runs a Futian port direct shuttle (one-hour cross-boundary) and has built one-stop cross-boundary diagnosis with multi-language service and direct insurance settlement.

Data and payment rails are being built. Shenzhen–Hong Kong medical-data cross-boundary security channels transmitted over 6.79 million medical files in four months. Under “payment connect”, Shenzhen’s first “medical insurance + commercial insurance” one-stop service centre supports overseas cards and digital RMB; six institutions connect to international insurers for instant settlement. Guangzhou’s ten measures on the medicine pass (issued 30 March 2026) add a quarterly Guangzhou–Hong Kong–Macao consultation mechanism, an RWS collaboration network, and support for commercial-insurance inclusion and cross-boundary electronic payment.

Practical pathways for foreign investors

  • For innovative products: treat the medicine pass as a China strategy, not a regional sideline. Identify clinical-need products already approved in Hong Kong/Macao, file through designated hospitals, and pair access with an RWS plan to generate national-registration evidence.
  • For services: use the Qianhai / Nansha / Hengqin platforms and the expanded wholly foreign-owned hospital pilot to establish or partner with international medical institutions; anchor on the “ten connect” model (institution, talent, medicine, service, ambulance, payment, data, education, guarantee, elderly care).
  • For payers and insurers: build direct-billing and commercial-insurance links; the GBA is piloting “medical insurance + commercial insurance” one-stop settlement and cross-boundary e-payment.
  • For evidence: collaborate with GBA hospitals on RWS; several multinationals already run such projects and the policy framework is explicit.
  • Compliance: the pass is bounded to designated hospitals and approved indications; products still need national registration for nationwide scale, and data crossing must follow the negative-list and security-channel rules.

Sources

Related reading

  • see also: GBA cross-boundary professional talent recognition (article 136)
  • see also: GBA foreign-invested enterprise tax and landing (article 135)
  • see also: Vocational training and education opening for foreign investors (article 138)

2026 大湾区:医疗健康产业外资机会(港澳药械通、跨境医疗服务)

概述

医疗健康是粤港澳大湾区对外资最具吸引力也最受监管的领域之一。2026 年两股力量交汇。其一,”港澳药械通”已从区域试点成熟为跨国创新者视为中国战略一部分的通道。其二,外商投资医疗服务——外商独资医院、港澳资机构、跨境医疗——的政策环境正被主动拓宽。对外资医疗集团而言,大湾区已不仅是销售市场,更是开展临床证据、试点跨境诊疗、布局区域运营的落脚点。

本文从三个层面梳理 2026 年的机会:借药械通导入创新药械、外资与港澳资医疗机构、跨境医疗服务与数据。

药械通:从试点到战略通道

2026 年 1 月 28 日在广州举行的跨国药企大湾区行座谈会,由广东省发展改革委(省大湾区办)主办,汇聚强生、辉瑞、阿斯利康、拜耳、诺华、艾伯维、赛诺菲等 15 家跨国药企高层与广东及九市政府。企业方的信号一致:大湾区市场潜力与创新生态使其成为战略要地,药械通是创新产品最快的入口。

药械通扩容迅猛。获批在粤港澳大湾区内使用的港澳药品、医疗器械,从 2023 年的 48 个增至 2026 年初的 146 个(另一说 149 个),指定医疗机构由 19 家扩展至 71 家、覆盖九市;截至 2026 年 4 月底,获批创新药械达 162 款(71 药品、91 器械),惠及超 1.7 万人次。广东已出台《广东省粤港澳大湾区内地九市进口港澳药品医疗器械管理条例》,规范申报、优化流程、提升效率。

对外资创新者,决定性优势是速度与证据。行业专家指出,相较传统注册路径,产品借药械通可在约 6 个月内完成准入;同样重要的是,药械通支持真实世界研究(RWS)——广东已出台配套政策,允许公立医院与企业合作开展 RWS 并细化申报流程。已有 7 家跨国药企与 4 家大湾区医疗机构开展 9 项真实世界研究。典型案例是辉瑞偏头痛药物瑞美吉泮,借助广州丰富医疗资源,仅三个月即完成前瞻性单臂多中心真实世界研究。

外资与港澳资医疗机构

服务端,前海出台其称为全国首个的支持港澳及外商医疗机构集聚发展政策,并推进外商独资医院试点。该集聚区已汇集 14 家国际化医疗机构、床位 4045 张,境外人士就诊量年增超 10%。在”人才通”下,深圳首名香港护士在前海注册执业,开设 6 家港式家庭医生工作室,44 名境外医疗专家常驻;”药械通”覆盖合作区内 5 家三级医院、累计获批 60 件、服务超 2300 人次;”救护通”实现”无下车通关、点对点直达”,转运时间压缩 80%。

2026 年 6 月商务部、国家发改委、财政部印发的《利用外资固稳促优行动方案》明确支持研究扩大外商独资医院试点区域范围。现有试点覆盖北京、上海、天津、南京、苏州、福州、广东、深圳及海南全岛 9 地,方案释放进一步扩围信号;同时支持将更多创新药械纳入商业保险保障、便利外资企业生产的药品进入零售渠道。

跨境医疗服务与数据

跨境诊疗正走向可运营。香港大学深圳医院作为大湾区跨境医疗标杆,是首批药械通试点医院,已引进 34 种国际药品、18 种器械,惠及超 7500 人次,近 100 名港籍医生执业;开通福田口岸直达专线(跨境单程 1 小时),构建一站式跨境诊疗、多语种服务与保险直付。

数据与支付通道正在搭建。深港医疗数据跨境安全通道上线 4 个月传输医疗文件超 679 万份;”支付通”建成深圳首家”医保+商保”一站式服务中心,支持境外卡与数字人民币,6 家机构接入国际商保实现即时结算。广州 2026 年 3 月 30 日发布的药械通”十条措施”新增穗港澳季度会商机制、真实世界研究协同网络,并支持纳入商保与拓展跨境电子支付。

外资企业的实操路径

  • 创新产品: 将药械通视为中国战略而非区域副线。识别已在港澳获批的临床急需产品,通过指定医院申报,并把准入与真实世界研究计划配对,为全国注册积累证据。
  • 医疗服务: 借助前海/南沙/横琴平台与扩围的外商独资医院试点设立或与国际化医疗机构合作,锚定”十个融通”模式(机构、人才、药械、服务、救护、支付、数据、科教、保障、养老)。
  • 支付与保险: 构建直付与商保链接;大湾区正试点”医保+商保”一站式结算与跨境电子支付。
  • 证据生成: 与大湾区医院合作开展 RWS,已有多家跨国药企落地项目,政策框架明确。
  • 合规: 药械通限定于指定医院与获批适应症;产品全国放量仍需国家注册,数据跨境须遵循负面清单与安全通道规则。

来源

相关阅读

  • 见:大湾区跨境专业人才资格互认(第 136 篇)
  • 见:大湾区外商独资企业落地与税收优惠(第 135 篇)
  • 见:外商投资职业教育与职业技能培训(第 138 篇)

Pharma opening measures under the 2026 action plan

  • The 2026 action plan supports rules for drug segmented manufacturing to facilitate overseas marketing-authorisation holders in cross-border segmented production.
    2026年行动方案支持出台药品分段生产细则,便利境外药品上市许可持有人开展跨境分段生产。
  • Pilot regions for biotechnology and wholly-foreign-owned hospitals will be further expanded.
    生物技术、外商独资医院开放试点区域将进一步扩大。
  • Insurers are encouraged to cover more innovative drugs and devices, and quality innovative products are brought into the retail channel.
    支持保险公司将更多创新药械纳入商业保险,推动优质创新药械进入零售渠道。
  • These are pharma-opening measures under the “stabilizing foreign investment” plan, complementing the general healthcare/pharma market-access brief.
    上述为”固稳促优”方案下的医药开放举措,与通用的医药医疗准入综述互为补充。
  • Eligibility and pilot regions are announced by the drug regulator and pilot-region authorities.
    资格与试点区域由药品监管及试点地区主管部门发布。
  • FIEs should assess segmented-manufacturing and hospital-pilot eligibility against their China strategy.
    外资企业应结合自身中国战略,评估分段生产与人独资医院试点的适用性。

Pharma opening measures under the 2026 action plan | 医药产业开放新措施

Overview

As part of the Action Plan for Stabilizing and Improving Foreign Investment (利用外资固稳促优行动方案), China is advancing a set of pharma and healthcare opening measures (issued 16 June 2026, 商资发〔2026〕97号; effective from 1 July 2026). These refine and extend the market-access path for foreign pharma and medtech companies, sitting alongside the general healthcare/pharma market-access framework.

This article focuses on the pharma-specific openings and is intended as a complement to the broader “Healthcare & pharma market access” brief.

Informational guidance only; exact eligibility and pilot regions are set by the drug regulator (NMPA) and pilot authorities, so verify before acting.

Measures at a glance

Drug segmented manufacturing

  • Study and issue rules for drug segmented manufacturing (药品分段生产实施细则).
  • Facilitate overseas marketing-authorisation holders (MAH) in conducting cross-border segmented manufacturing of biologics and chemical drugs.
  • Allows foreign MAHs to split the manufacturing process across sites/jurisdictions under defined rules, supporting flexible global supply.

Biotech and wholly-foreign-owned hospital pilots

  • Expand pilot regions for biotechnology and wholly-foreign-owned hospitals (外商独资医院).
  • Build an industry collaboration platform to help foreign-invested enterprises’ drugs enter the retail channel.

Insurance coverage and retail access

  • Encourage insurers to include more innovative drugs and devices in commercial insurance coverage.
  • Continuously encourage quality innovative drugs and devices to enter the China market.

How it relates to the broader access brief

  • The general Healthcare & pharma market access article covers NMPA registration, licensing and the baseline path for foreign pharma/medtech entry.
  • This brief covers the 2026 policy increments — segmented manufacturing, expanded pilots, and insurance/retail access — that lower specific frictions for foreign players.
  • Read both: the access brief for the baseline; this brief for the newest openings.

What to do next

  • Foreign MAHs: assess whether segmented manufacturing fits your supply chain and watch for the implementing rules and eligible sites.
  • Medtech/pharma groups: track expanded biotech and wholly-foreign-owned hospital pilot regions for location and eligibility.
  • Market-access teams: engage insurers and retail channels early to plan commercial-insurance and retail access for innovative products.
  • Coordinate with the drug regulator (NMPA) and pilot-region authorities on eligibility and application windows.
  • Combine this brief with the general market-access article when building your China pharma entry plan.

Sources

  • 中华人民共和国中央人民政府(国务院)— 《利用外资固稳促优行动方案》全文:https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm
  • 国家药品监督管理局(官方门户)— https://www.nmpa.gov.cn
  • 商务部 — 关于印发《利用外资固稳促优行动方案》的通知(商资发〔2026〕97号):https://tradeinservices.mofcom.gov.cn/article/zcfb/zcfg/202606/183553.html

Related reading

  • see also: Healthcare & pharma market access (NMPA) / 医疗医药准入(药监局)
  • see also: Stabilizing Foreign Investment Action Plan: 15 measures at a glance / 利用外资固稳促优行动方案:15条举措总览

医药产业开放新措施

概述

作为《利用外资固稳促优行动方案》的一部分,中国推进一组医药与医疗开放举措(2026年6月16日印发,商资发〔2026〕97号;自2026年7月1日起落地)。这些举措细化并延伸了外资医药与医疗器械企业的准入路径,与通用的医药医疗准入框架并行。

本文聚焦医药专项开放,旨在作为更广泛”医疗医药准入”综述的补充。

本文仅为信息性指引;具体资格与试点区域由药品监管(NMPA)及试点主管部门规定,行动前请核实。

举措一览

药品分段生产

  • 抓紧研究出台药品分段生产实施细则。
  • 便利境外药品上市许可持有人(MAH)开展生物制品、化学药品的跨境分段生产。
  • 在既定规则下,允许境外 MAH 将生产环节跨场地/辖区拆分,支撑灵活的全球供应。

生物技术与人独资医院试点

  • 扩大生物技术与外商独资医院开放试点区域。
  • 搭建行业协作平台,便利外资企业生产的药品进入零售渠道。

商保覆盖与零售可及

  • 支持保险公司将更多创新药械纳入商业保险保障范围。
  • 持续鼓励优质创新药械进入中国市场。

与通用准入综述的关系

  • 通用的医疗医药准入文章涵盖 NMPA 注册、许可及外资医药/器械来华的基线路径。
  • 本文涵盖2026年政策增量——分段生产、试点扩围、商保与零售可及——即降低外资特定摩擦的举措。
  • 两篇对照阅读:准入综述看基线,本文看最新开放。

下一步建议

  • 境外 MAH:评估分段生产是否契合供应链,关注实施规则与合格场地。
  • 医疗器械/医药集团:跟踪生物技术与人独资医院试点扩围的区域与资格。
  • 市场准入团队:尽早对接保险与零售渠道,规划创新产品的商保与零售可及。
  • 就资格与申报窗口,与药品监管(NMPA)及试点地区主管部门协同。
  • 制定中国医药入华方案时,将本文与通用准入综述结合使用。

来源

  • 中华人民共和国中央人民政府(国务院)— 《利用外资固稳促优行动方案》全文:https://www.gov.cn/zhengce/zhengceku/202606/content_7072838.htm
  • 国家药品监督管理局(官方门户)— https://www.nmpa.gov.cn
  • 商务部 — 关于印发《利用外资固稳促优行动方案》的通知(商资发〔2026〕97号):https://tradeinservices.mofcom.gov.cn/article/zcfb/zcfg/202606/183553.html

相关阅读

  • see also: 医疗医药准入(药监局) / Healthcare & pharma market access (NMPA)
  • see also: 利用外资固稳促优行动方案:15条举措总览 / Stabilizing Foreign Investment Action Plan: 15 measures at a glance